‰F’ˆq‹óŠÂ‹«ˆãŠw Vol. 53, No. 2, 23-35, 2016

Œ´’˜

Wolff-Parkinson-WhiteÇŒóŒQ“™C–[Žº•p–¬«•s®–¬‚Ìq‹óˆãŠw“K«•]‰¿‹y‚Ñ”»’è–@‚ÉŠÖ‚·‚錟“¢

îà“c@–M•vC—§‰Ô@³ˆê

–h‰qˆã‰È‘åŠwZ–h‰qˆãŠwŒ¤‹†ƒZƒ“ƒ^[ˆÙíŠÂ‹«‰q¶Œ¤‹†•”–å

A Review of Evaluating and Assessing Aeromedical Fitness of Pilots with Wolff-Parkinson-White Syndrome or Atrioventricular Tachyarrhythmias

Kunio Takada, Shoichi Tachibana

Division of Environmental Medicine, National Defense Medical College Research Institutey

ABSTRACT
@In this review, we defined the mechanisms by which macro-reentry circuits in the atrioventricular region evoke paroxysmal supraventricular tachycardia as gatrioventricular tachyarrhythmias iAVTjh and hemodynamic aberrance, based on AVT as ghemodynamic phenomena iHDPjh.@HDP is an aeromedical concern among pilots who become incapacitated during flight.@The assessment of aeromedical fitness, hereafter referred to as gfitnessh, of the pilot should be performed with caution in order to obtain precise clinical findings.@Herein, we propose methods to evaluate and assess aeromedical fitness of pilots for AVT, based on our review of the literature.
@In cases with a history of HDP, when all of the reentry circuits are presumed as being functional based upon an electrophysiological study iEPSj, in principle the pilot is qualified as exhibiting fitness without restriction, otherwise the pilots are not considered fit.
@In cases with Wolff-Parkinson-White iWPWj syndrome without a history of HDP and EPS, those pilots aged 40 years or more, exhibit fitness restricted to low-G aircraft.@If the pilot is less than 40 years of age, they would have fitness restricted to multicrew operations and low-G aircraft.@To remove the restriction, the following procedures may be performed;1j exhibiting both a QRS≦120 msec and Rosenbaum type B on electrocardiography, which would indicate a fasciculoventricular pathway iFVPj that would not develop to HDP;2j The characteristic waveform is presumed from FVP based on no alteration in the QRS waveform using Holter electrocardiogram or adenosine test;and 3j long anterograde effective refractory period is presumed based on intermittent WPW syndrome or disappearance of the delta wave on exercise testing.@In cases with Lown-Ganong-Levine syndrome, which we defined as sustained PR interval <110 msec despite repeated testing, without a history of HDP and EPS, the pilot would have fitness restricted to multicrew operations and low-G aircraft.@To remove the restriction, the observation of no alteration in the QRS waveform on Holter electrocardiogram or adenosine test, which is presumed as not having any apparent alternative pathway, may be performed.

iReceived:13 July, 2015@Accepted:18 March, 2016j

Key words:Wolff-Parkinson-White syndrome, pre-excitation syndrome, paroxysmal supraventricular tachycardia, aviation medicine, waiver

I.@Œ¾

@㎺«‚É“d‹C“I‹»•±‚̃}ƒNƒƒŠƒGƒ“ƒgƒŠ[‹@˜‚É‚æ‚é”­ì«ãŽº•p”iparoxysmal supraventricular tachycardia: PSVTj‚ð‹N‚±‚·Ž¾Š³‚ÍCˆÈ‰º‚̂悤‚È“ñ‚‚̔­Ç•”ˆÊ‚É•ª—Þ‚Å‚«‚éB

@‡@@–[ŽºŠÔ‚ðŒ‹‚Ô•›“`“±˜H–”‚Í–[ŽºŒ‹ß‚ð‰î‚µ‚Ä“d‹C“I‹»•±‚ªù‰ñ‚·‚é‚à‚ÌC–”‚ÍC‚»‚Ì”­Ç‚̉”\«‚ª‚ ‚é‚à‚Ìi–[Žº—̈æjB

@‡A@–[“à‚ÉŒÀ‹Ç‚µ‚½“d‹C“I‹»•±‚ðù‰ñ‚·‚é‚à‚ÌiS–[jB

@‡@ ‚ÉŠY“–‚·‚é‚à‚Ì‚ÍC–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[•p”iatrioventricular nodal re-entrant tachycardia:AVNRTjC–[ŽºƒŠƒGƒ“ƒgƒŠ[•p”iatrioventricular re-entrant tachycardia: AVRTjCpermanent form of junctional atrioventricular reciprocating tachycardiaiPJRTjCWolff-Parkinson-WhiteiWPWjÇŒóŒQ‹y‚ÑLown-Ganong-LevineiLGLjÇŒóŒQ“™‚Ì‘Šú‹»•±ÇŒóŒQipre-excitation syndrome: PESj“™‚ª‹“‚°‚ç‚ê‚éB‚È‚¨CPES‚ÍC–[Žº—̈æ‚Ƀ}ƒNƒƒŠƒGƒ“ƒgƒŠ[‰ñ˜H‚ªŒ`¬‚³‚ê‚Ä‚¨‚èCPSVT‚ɉÁ‚¦CS–[ד®iatrial fibrillation:Afj–”‚ÍS–[‘e“®iatrial flutter:AFj‚ðˆø‚«‹N‚±‚µC‚»‚̈ꕔ‚ÉSŽº•p”iventricular tachycardia:VTj‚âSŽº×“®iventricular fibrillation:Vfj‚𵂭‰Â”\«‚Ì‚ ‚鎾Š³ŒQ‚Å‚ ‚é7,11jB‡A ‚ÉŠY“–‚·‚é‚à‚Ì‚ÍCAF‹y‚ÑS–[•p”iatrial tachycardia: ATj‚ÌS–[“à‚̃ŠƒGƒ“ƒgƒŠ[•p”‚ª‹“‚°‚ç‚ê‚é10j‚ª ‡A ‚ɂ‚¢‚Ä‚Í•Ê‚Ì‹@‰ï‚ÉŒŸ“¢‚ðs‚¢C‚±‚±‚Å‚Í ‡@ ‚Ì‚Ý‚ðŽæˆµ‚¢‚½‚¢B

@‚±‚±‚Å‚ÍC–[Žº—̈æ‚̃}ƒNƒƒŠƒGƒ“ƒgƒŠ[‹@˜‚É‚æ‚èPSVT“™‚ð‹N‚±‚·•a‘Ô‚ðu–[Žº•p–¬«Ž¾Š³iatrioventricular tachyarrhythmias:AVTjv‚ƌĂÑCAVT‚É‚æ‚è“®œ§C‚ß‚Ü‚¢CŽ¸_“™‚ÌzŠÂ“®‘Ԃ̈Ùí‚ðuŒŒ—¬—ÍŠw“IŒ»Ûihemodynamic phenomena:HDPjv‚ƌĂԂ±‚Æ‚Æ‚·‚éB

@HDP‚ð”F‚ß‚½ê‡‚ÍCq‹óˆãŠw“I‚ÉCd‘厖ŒÌ‚ÌŒ´ˆö‚̈ê‚‚Æl‚¦‚é‚ׂ«‚Å‚ ‚èC“KØ‚Èf’f‚É‚æ‚èCq‹óˆãŠw“K«iˆÈ‰ºu“K«v‚Æ‚¢‚¤j‚ð”»’f‚µ‚È‚¯‚ê‚΂Ȃç‚È‚¢Bu“K«v‚Æ‚ÍC‡@ q‹ó‹Æ–±‚ðŽÀŽ{‚·‚邽‚ß‚É•K—v‚ÈSg‚Ìó‘Ô‚ªˆê’è…€‚É‚ ‚邱‚ÆC‚·‚È‚í‚¿C‚ ‚ç‚ä‚é󋵉º‚ňÀ‘S‚É”òs‚·‚邽‚ß‚É•K—v‚È…€ˆÈã‚ÉSg‚Ìó‘Ô‚ª‚ ‚邱‚ÆC‡A ‚±‚Ìó‘Ô‚ª—LŒøŠúŠÔ’†ˆÛŽ‚³‚ê‚é‚Æ—\‘z‚³‚ê‚邱‚ÆC‚ðŽw‚·13jB

@‚킪‘‚Ì–¯ŠÔq‹ó‚É‚¨‚¢‚ÄCˆÈ‰º‚ÌꇂÍq‹óg‘ÌŒŸ¸ƒ}ƒjƒ…ƒAƒ‹‚É‹LÚ‚³‚ê‚Ä‚¢‚ég‘ÌŒŸ¸Šî€‚ÉŠî‚«•s“K‡‚Å‚ ‚èCq‹ó‹Æ–±‚ðs‚¤‚±‚Æ‚ªo—ˆ‚È‚¢13jB‚±‚±‚É‚¨‚¯‚éu•s“K‡v‚Æ‚ÍC‹K‘¥‚Å’è‚ß‚ç‚ꂽˆÈ‰º‚ÉŽ¦‚·g‘ÌŒŸ¸Šî€‚ð–ž‚½‚³‚È‚¢ê‡‚ðŽw‚·B

@‡@@ˆê‰ß«Žá‚µ‚­‚ÍŽ‘±«‚Ì㎺•p”isupraventricular tachycardia:SVTj–”‚ÍAf/AF–”‚Í‚»‚ÌŠù‰—ð‚ª‚ ‚é‚à‚ÌB

@‡A@WPWÇŒóŒQ‚Ì‚¤‚¿C”­ì«•p”‚𔺂¤‚à‚ÌC–”‚Í‚»‚ÌŠù‰—ð‚Ì‚ ‚é‚à‚ÌB

@‡B@‚»‚Ì‘¼S“d}ãCd‘å‚ÈSŽ¾Š³‚ð„’è‚Å‚«‚é‚à‚ÌB

@‡C@’²—¥ˆÙí‚ɑ΂µ‚ÄNP“IŽ¡—ÃiƒJƒe[ƒeƒ‹S‹ØÄŽÜp“™j‚ðs‚Á‚½‚à‚ÌB

@q‹óŽ©‰q‘à‚É‚¨‚¢‚ÄCˆÈ‰º‚Ìꇂ͕s“K‡i•s‡Šij‚Æ‚È‚èC–¯ŠÔq‹ó‚Æ‘½­ˆÙ‚È‚Á‚½ˆÈ‰º‚̂悤‚È“à—e‚Æ‚È‚Á‚Ä‚¢‚é12jB

@‡@@•p””­ì‚Å”½•œ«C‚©‚ÂÇó‚𔺂¤‚à‚ÌB

@‡A@Ž‘±«‚Ì”­ì«•p”CAF–”‚ÍAfB

@‡B@WPWÇŒóŒQ‚Å”­ì«•p”‚𔺂¤‚à‚ÌB‚½‚¾‚µCŒŸ¸bi‘€cŽmŒó•âŽÒ‚Ì“K«”»’èj‚Å‚ÍCWPWÇŒóŒQ‚ª‚È‚¢‚±‚ÆB

@‡C@‚»‚Ì‘¼S“d}ãCd‘å‚ÈSŽ¾Š³‚ð„’è‚Å‚«‚é‚à‚ÌB

@•s“K‡‚Æ‚³‚ê‚Ä‚àCq‹ó‹Æ–±‚ðŠó–]‚·‚éŽÒ‚ÍCŠ—v‚̸–§ŒŸ¸‚ðs‚¢C•K—v‚ɉž‚¶‚ÄŽ¡—Âðs‚¢CÇó“™‚ªˆÀ’肵‚Ä‚¢‚邱‚Æ‚ªŠm”F‚³‚ê‚Ä‚©‚çCƒEƒF[ƒo[iWaiverjR¸‚ð\¿‚·‚邱‚Æ‚ª‚Å‚«‚éBƒEƒF[ƒo[R¸‚Æ‚ÍC•s“K‡‚Æ‚³‚ꂽŽÒ‚ɑ΂µ‚ÄC‚»‚ÌŽÒ‚ÌŒoŒ±‹y‚Ñ”\—Í‚ðl—¶‚µ‚ÄCR¸‚ÌŒ‹‰ÊC‚»‚Ì•s“K‡Ž–€‚ªq‹óˆÀ‘S‚ð‹º‚©‚³‚ê‚È‚¢‚Æ”»’肳‚ê‚éꇂɌÀ‚èCg‘ÌŒŸ¸Šî€‚É“K‡‚·‚é‚Æ‚Ý‚È‚·‚±‚Æ‚ª‚Å‚«‚駓x‚Å‚ ‚è13jC‚±‚±‚Å‚ÍC‡Ši‚Ìꇂðu“K«‚ð—L‚·‚évC•s‡Ši‚Ìꇂðu“K«‚ðŒ‡‚­v‚Æ•\‹L‚·‚éB‰Á‚¦‚ÄCg‘ÌŒŸ¸Šî€‚É“K‡‚·‚é‚©”»’袓ï‚È—á‚ɑ΂µ‚Ä‚àCƒEƒF[ƒo[R¸‚ð\¿‚µC•]‰¿‹y‚Ñ”»’è‚ðŽó‚¯‚邱‚Æ‚à‚Å‚«‚é11jB‚È‚¨C“¯—l‚ȧ“x‚ÍŽ©‰q‘à‚É‚à‘¶Ý‚·‚é12,14jB‚‚܂èC“K«‚ÉŠÖ‚µ‚ÄÚׂȌŸ“¢‚ðs‚¤ê‡‚ÍCŒ´‘¥ƒEƒF[ƒo[R¸‚ðs‚¤‚±‚Æ‚É‚È‚éB

@‚±‚±‚Å‚ÍC‘“àŠO‚Ì—Õ°ˆãŠw“I’mŒ©‹y‚Ñq‹óˆãŠw“I’mŒ©‚ÌŒŸõ‚ðs‚¢CAVT‚ª”F‚ß‚ç‚ê‚é—á‚Ì“K«•]‰¿‹y‚Ñ”»’è–@‚ðŒŸ“¢‚µ‚½‚¢B‚È‚¨C“–˜_•¶‚ÍCŒ´‘¥‚Æ‚µ‚ÄAVT‚Ì‚Ý‚ª”F‚ß‚ç‚ê‚Ä‚¢‚éꇂð‘z’肵‚Ä‚¢‚é‚Ì‚ÅC‘¼‚ÌŠî‘bŽ¾Š³‚Ì•û‚ª•a‘Ô‚É‘å‚«‚ȉe‹¿‚ð‹y‚Ú‚·ê‡‚ÍC•Ê“rŒŸ“¢‚ª•K—v‚Å‚ ‚éB

II.@—Õ°ˆãŠw“I’mŒ©

@–{ŒŸ“¢‚É•K—v‚È’mŒ©‚ÉŠÖ‚µ‚Ä‚ÍCŽå‚Æ‚µ‚ÄCu—Õ°S‘Ÿ“d‹C¶—ŒŸ¸ielectrophysiological study:EPSj‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“iˆÈ‰ºuEPSƒKƒCƒhƒ‰ƒCƒ“v‚Æ‚¢
‚¤jv21jCu•s®–¬‚Ì”ñ–ò•¨Ž¡—ÃKƒCƒhƒ‰ƒCƒ“iˆÈ‰ºu”ñ–ò•¨Ž¡—ÃKƒCƒhƒ‰ƒCƒ“v‚Æ‚¢‚¤jv23j‹y‚ÑuƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“iˆÈ‰ºuƒAƒuƒŒ[ƒVƒ‡ƒ“v‚Æ‚¢‚¤j‚Ì“K‰ž‚ÆŽè‹Z‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“iˆÈ‰ºuƒAƒuƒŒ[ƒVƒ‡ƒ“ƒKƒCƒhƒ‰ƒCƒ“v‚Æ‚¢‚¤jv22j‚ÉŠî‚­‚Æ‚æ‚¢‚Æl‚¦‚ç‚ê‚éBf’f–@‹y‚ÑŽ¡—Ö@“™‚ÌÚׂɊւµ‚Ä‚ÍCŽå‚Æ‚µ‚Ä‚±‚ê‚çƒKƒCƒhƒ‰ƒCƒ“‚É÷‚邪C‚»‚Ì’†‚Å‚àq‹óˆãŠw“I‚Éd—v‚ÈŽ–€‚ð‹LÚ‚·‚éB‚È‚¨C‚±‚ê‚ç‚̃KƒCƒhƒ‰ƒCƒ“‚Ì‚Ý‚Å‚ÍŒŸ“¢‚·‚é‚Ì‚É•s\•ª‚Æl‚¦‚ç‚ê‚é‚Ì‚ÅC‚»‚Ì‘¼‚Ì•ñ“™‚à‰Á‚¦‚éB

@A.@PES‚𜂭AVT

@1.@•a‘Ô

@Table 1‚É‚Í“–ŠY˜_•¶‚Ŏ戵‚¤Ž¾Š³‚ðŽ¦‚µ‚½B

@AVNRT‚ÍCæ“V“I‚É”F‚ß‚é–[ŽºŒ‹ß“ñd“`“±˜Hifast pathway‚Æslow pathwayj‚̃ŠƒGƒ“ƒgƒŠ[•p”‚𶂶‚é‚à‚Ì‚ð‚¢‚¤BSlow pathway‚ð‡sCfast pathway‚ð‹ts‚·‚é‚à‚Ì‚ðslow-fasti–”‚Í’ÊíŒ^jAVNRT‚ƌĂÔB‚»‚Ì‹t‚ðfast-slow AVNRT‚ƌĂÑC‚»‚Ì‘¼Cslow-slow AVNRT‚à‘¶Ý‚µC‚»‚ê‚ç‚ð”ñ’ÊíŒ^AVNRT‚ƌĂԂ±‚Æ‚ª‚ ‚éBSlow-fast AVNRT‚ª‘S‘Ì‚Ì80%ˆÈã‚ðè‚ß‚é16jB

@AVRT‚ÍC–[ŽºŠÔ‚Éæ“V“I‚É”F‚ß‚é•›“`“±˜H‚Æ–[ŽºŒ‹ß‚Ì“ñ‚‚̌o˜H‚Ì‚¤‚¿Cˆê•û‚ðS–[‚©‚çSŽº‚ÉC‘¼•û‚ðSŽº‚©‚çS–[‚É‹»•±‚ª“`“±‚µƒŠƒGƒ“ƒgƒŠ[«‚Ì•p”‚𶂶‚é‚à‚Ì‚ð‚¢‚¤BAVRT‚ðˆø‚«‹N‚±‚·‚à‚Ì‚Æ‚µ‚ÄCWPWÇŒóŒQ‚ª‚ ‚é21jBAVRT‚Ì‹H‚È•a‘Ô‚Æ‚µ‚ÄCPJRT‚ÍCŽº–[“`“±‚ª–[ŽºŒ‹ß-His-PurkinjeŽhŒƒ“`“±Œn‚ð‰î‚³‚¸C’·‚¢“`“±ŽžŠÔ‚ð‚à‚•›“`“±˜Hi‚¢‚í‚ä‚éslow Kent‘©j‚ð‰î‚·‚é‚à‚Ì‚ðŽw‚·21jB

@‚È‚¨CAVNRT‹y‚ÑAVRT‚ÅPSVT‘S‘Ì‚Ì90%ˆÈã‚ðè‚ß‚é‚Æ‚³‚ê‚é10jB

Table 1.@Disorder schema in this document.
@@ –[Žº•p–¬«Ž¾Š³ –[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[•p” ’ÊíŒ^:slow-fast
i‘Šú‹»•±ÇŒóŒQ‚𜂭j ”ñ’ÊíŒ^:fast-slow
”ñ’ÊíŒ^:slow-slow
–[ŽºƒŠƒGƒ“ƒgƒŠ[•p” ³í•›“`“±˜H
PJRT
@@ ‘Šú‹»•±ÇŒóŒQ Wolff-Parkinson-WhiteÇŒóŒQ Œ°«
ŠÔŒ‡«
öÝ«
Lown-Ganong-LevineÇŒóŒQ
‚»‚Ì‘¼‚Ì‘Šú‹»•±ÇŒóŒQ
@@PJRT:permanent form of junctional atrioventricular reciprocating tachycardiaD


Fig. 1. Algorithm to differentiate narrow QRS tachycardia
 AT:atrial tachycardia, PJRT:permanent form of junctional atrioventricular reciprocating tachycardia,
 AVNRT:atrioventricular nodal re-entrant tachycardia, ANRT:atrioventricular re-entrant tachycardia imodified from reference 21 and reformedj.

@2.@f’f

@QRSƒ120 msec‚Ì•p”iS””≧100 bpmj‚ÍNarrow QRS •p”‚ƌĂ΂êCPSVTC“´«•p–¬CAFi2:1“`“±j‚É”F‚ß‚ç‚êCVT‚É‚Í”F‚ß‚ç‚ê‚È‚¢BPSVT‚Ì’†‚Å‚àClong RP •p”iQRS”g’¼‘O‚ÉP”g‚ª‚ ‚é‚à‚Ìj‚ÍATCPJRT–”‚Ífast-slow AVNRT‚ÉCshort RP •p”iQRS”g’¼Œã‚ÉP”g‚ª‚ ‚é‚à‚Ìj‚ÍŽå‚Æ‚µ‚ÄAVRT–”‚Íslow-slow AVNRT‚ÉCP”g‚ª•s–¾‚ÈꇂÍslow-fast AVNRT‚É”F‚ß‚ç‚ê‚é18jBFig. 1‚É‚ÍCnarrow QRS •p”‚̊ӕʂ̃tƒ[ƒ`ƒƒ[ƒg‚ðŽ¦‚·21jBˆê•ûCwide QRS•p”‚ÍCQRS≧120 msec‚Ì•p”‚ðŽw‚µC’ÊíCVT‚Ìꇂł ‚邪C‹rƒuƒƒbƒN“™‚Ì•Ïs“`“±‚𔺂¤PSVT‚Ìê‡‚à‚ ‚éBPSVT‚Å‚Í’ÊíC–[Žº‰ð—£CQRS≧140 mseci¶‹rƒuƒƒbƒNŒ^‚Å‚ÍCQRS≧160 msecjC¶Ž²•ÎˆÊi“Á‚É“d‹CŽ²≦|30°j“™‚Í”F‚ß‚ç‚ꂸCV1—U“±‚ÅŽO‘Š«i‚½‚¾‚µCtaller left rabbit eariRsrL”gŒ`‚ðŽ¦‚·‚à‚Ì:¶‚ÌR”g‚ª‘å‚«‚¢‚à‚Ìj‚𜂭j‚ðŽ¦‚·20jB

Fig. 1.@TMT results in 264 volunteers ifeasibility studiesj.
a.@Comparison of first and second TMT measurements.
In order to verify the precision of the thermometer we used, healthy volunteers were asked to measure their TMT twice.@We then compared the two measurements.@There was no significant difference between the first and second TMT measurements. TMT:tympanic membrane temperature.
b.@Variation of TMT with environmental temperature.
We also determined whether environmental temperature influenced the TMT of healthy volunteers.@Environmental temperature did not significantly affect TMT values.

@d—v‚Æ‚È‚é‚Ì‚ÍCAVRT‚ÆAT‚ÌŠÓ•Ê‚Å‚ ‚éBAT‚Ì‘½‚­‚Í”­ìŽž‚ÌS“d}‚Åf’f‚³‚ê‚邱‚Æ‚©‚çCPSVT‚É•ª—Þ‚³‚ê‚éꇂª‘½‚¢BAT‚ÍS–[“à‚ÉŒÀ‹Ç‚µ‚½ˆÙí“d‹C‹»•±‚ª100-240 bpm‚ÅŒ»‚êCP-PŠÔ‚É“™“dˆÊü‚ª‚ ‚é‚à‚Ì‚ðŽw‚·BS“d}ãCP”g‚ÍQRS”g‚Ì‘O‚É–¾—Ä‚É”F‚ß‚ç‚ê‚邪CS””‚ª‘½‚¢ê‡‚ÍCæsS”‚ÌT”g‚Æd‚È‚è•s–¾—Ä‚È‚±‚Æ‚ª‚ ‚èCEPS‚É‚æ‚éfast-slow AVNRT–”‚ÍPJRT‚Æ‚ÌŠÓ•Ê‚ª•K—v‚É‚È‚éꇂª‚ ‚é32jB

@‚È‚¨CPJRT‚ÍCS“d}ãCIICIIICaVFCV5-6‚ʼnA«P”g‚ªŒ©‚ç‚ê‚éincessant typei•p”­Œ^j‚Ìlong RP•p”‚Å‚ ‚é4jB

@B.@PES

@1.@•a‘Ô

@PES‚ÍCWPWÇŒóŒQ‹y‚Ñ‚»‚̈ŸŒn8jC–[ŽºŠÔ‚É–[ŽºŒ‹ßˆÈŠO‚Ì•›“`“±˜H‚ð”F‚ß‚é‚à‚ÌiS“d}ãCPRŽžŠÔ‚Ì’Zk‚ðŽ¦‚·‚à‚Ìj‚ðŽw‚·‚悤‚Å‚ ‚邪C’è‚Ü‚Á‚½Œ©‰ð‚É–R‚µ‚¢BŒ»ÝCWPWÇŒóŒQ‚Ì‘¼CLGLÇŒóŒQ‚É•ª—Þ‚·‚錩‰ð‚ª‚ ‚é21jB

@WPWÇŒóŒQ‚ÍC]—ˆKent‘©—R—ˆ‚É‚æ‚é‚à‚Ì‚Æl‚¦‚ç‚ê‚Ä‚¢‚½‚ªCÅ‹ß‚ÍC‘©Ž}SŽº“`“±˜Hifasciculoventricular pathway:FVPj—R—ˆ‚Ì•a‘Ô‚àŠÜ‚Ü‚ê‚é‚Æ‚·‚錩‰ð‚ª‚ ‚é27jB

@Kent‘©:æ“V“I‚É”F‚ß‚ç‚ê‚éS–[‚ÆSŽºŠÔ‚É–[ŽºŒ‹ßˆÈŠO‚Ì•›“`“±˜HB

@FVP:–[ŽºŒ‹ß–”‚ÍHis‘©‚©‚çSŽº‹Ø‚ÖŽŠ‚éüˆÛ‘©‚ðŽw‚·‚à‚Ì‚Æ‚³‚ê‚邪C‡s«Œ¸Š“`“±“Á«‚ð—L‚·‚é•›“`“±˜H‘S”Ê‚ðŽw‚·‚Æ‚¢‚¤ˆÓŒ©‚à‚ ‚é21jB

@Œ¸Š“`“±:‘OŽhŒƒ‚©‚玟ŽhŒƒ‚ª“ü‚é‚Ü‚Å‚ÌŽžŠÔi˜AŒ‹Šúj‚ª’Z‚­‚È‚é‚Æ“`“±ŽžŠÔ‚ª’·‚­‚Ȃ邱‚Æ‚ðŽw‚µC–[ŽºŒ‹ß‚â“´Œ‹ß“™CŒ‹ß×–E“Á—L‚Ì“`“±“Á«‚ðŽw‚·B

@LGLÇŒóŒQ‚̬ˆö‚ɂ‚¢‚Ä‚ÍCJamesüˆÛCS–[-His‘©•›“`“±˜HC–[ŽºŒ‹ß’áŒ`¬C–[ŽºŒ‹ß“`“±˜´iienhanced atrioventricular nodal conduction:EAVNCj–”‚Í–[ŽºŒ‹ß“ñd“`“±˜H‚Ì‘¬“`“±˜Hifast pathwayj‚Ì“`“±˜´i“™‚ª‹“‚°‚ç‚êCPRŽžŠÔ‚Ì’Zk‚ɂ‚¢‚Ä‚Í•¡”‚̬ˆö‚ªl‚¦‚ç‚ê‚Ä‚¢‚é21jB

@JamesüˆÛ:“´Œ‹ß‚Æ–[ŽºŒ‹ß‚ð˜A—‚·‚é3–{‚ÌŒ‹ßŠÔ˜Hi‘OC’†CŒãj‚Ì“àCŒãŒ‹ßŠÔ˜H‚ª“´Œ‹ß‚̌㉂©‚ço‚ÄC–[ŽºŒ‹ß‚Ì‘å•”•ª‚ðƒoƒCƒpƒX‚µ‚ÄC‚»‚̉º•û‚ųíŽhŒƒ“`“±Œn‚ƘAŒ‹‚µ‚½•›“`“±˜HB

@2.@f’f

@WPWÇŒóŒQ‚ÍCS“d}ãCSŽº‘Šú‹»•±‚𔽉f‚·‚éC‡@ short PRŽžŠÔiPRƒ120 msecjC‡A QRS„100 msecC‡B ƒfƒ‹ƒ^”gC‚ðŽ¦‚µC’ÊíCÇó‚𔺂¤‚à‚Ì‚Æ‚³‚ê‚é21jB‚½‚¾‚µC–{ŒŸ“¢‚É‚¨‚¢‚Ä‚Í–³ÇŒó‚ÌꇂàWPWÇŒóŒQ‚Æ‚¢‚¤‚±‚Æ‚Æ‚·‚éB‚»‚Ì“Á’¥“IS“d}ŠŒ©‚ªPí“I‚É”F‚ß‚ç‚ê‚錰«WPWÇŒóŒQCŠÔŒ‡“I‚ÉoŒ»‚·‚éŠÔŒ‡«WPWÇŒóŒQC•›“`“±˜H‚Í‘¶Ý‚·‚邪‚»‚̇s«“`“±‚ð—L‚³‚¸‹ts«“`“±‚Ì‚Ý‚ð—L‚µ“Á’¥“IS“d}ŠŒ©‚ð—L‚µ‚È‚¢öÝ«WPWÇŒóŒQ‚Æ‚¢‚¤•ª—Þ‚ª‚ ‚é21jB‚È‚¨CRosenbaum‚ç‚Í‚»‚ÌS“d}”gŒ`‚©‚çˆÈ‰º‚̂悤‚É•ª—Þ‚µ‚Ä‚¢‚é26jB

@AŒ^:V1‚ÅRƒpƒ^[ƒ“iR/S”ä„1j‚ðŽ¦‚·‚à‚ÌB

@BŒ^:V1‚ÅrS ƒpƒ^[ƒ“iR/S”äƒ1j‚ðŽ¦‚·‚à‚ÌB

@PES‚É‚ÍCWPWÇŒóŒQ‚Ì‘¼Cshort PRŽžŠÔiPRƒ120 msecj‚ð”F‚ß‚é‚à‚Ì‚ÌQRS”g‚ͳí‚Å‚ ‚éLGLÇŒóŒQ‚Æ‚¢‚¤Ž¾Š³ŠT”O‚ª‚ ‚èC‚»‚Ìf’f‚É‚ÍPSVTCAf/AF‚ÌŠù‰‚ð—L‚·‚é•K—v‚ª‚ ‚é‚Æ‚³‚ê‚é7jB‚½‚¾‚µC–{ŒŸ“¢‚É‚¨‚¢‚Ä‚Í–³ÇŒó‚ÌꇂàLGLÇŒóŒQ‚Æ‚¢‚¤‚±‚Æ‚Æ‚·‚éB

@‚‚܂èCPSVT“™‚ð”­Ç‚µ‚Ä‚¢‚È‚¢AVT‚ÍCPESˆÈŠOf’f‚³‚ê‚È‚¢‚±‚Æ‚Æ‚È‚èCPESˆÈŠO‚ÌAVT‚ÍPSVT“™‚Ì”­Ç‚ð‚«‚Á‚©‚¯‚Éf’f‚³‚ê‚é‚à‚Ì‚Å‚ ‚éB

@–³ÇŒó‚ÌPES‚Ì•]‰¿‚ɃAƒfƒmƒVƒ“ƒeƒXƒg‚Ì—L—p«‚ðŽå’£‚·‚錤‹†ŽÒ‚à‚¢‚é6,27jBƒAƒfƒmƒVƒ“ƒeƒXƒg‚Æ‚ÍCƒAƒfƒmƒVƒ“ŽOƒŠƒ“Ž_‚ð‹}‘¬–O˜a‚·‚邱‚Ƃňꎞ“I‚É–[ŽºƒuƒƒbƒN‚ð쬂µCQRS”g‚ÌŒ`‘Ԃ̕ω»‚ª”F‚ß‚ç‚ꂽê‡C•›“`“±˜H‚ɃŠƒGƒ“ƒgƒŠ[‹@”\‚ð—L‚·‚é‚Æ•]‰¿‚·‚é‚à‚Ì‚Å‚ ‚é27jBFig. 2‚É‚ÍCƒAƒfƒmƒVƒ“ŽOƒŠƒ“Ž_‚ð‹}‘¬–O˜a‚É‚æ‚éQRS”g‚ÌŒ`‘Ԃ̕ω»‚ðŽ¦‚µ‚½—á‚ðŽ¦‚·27jB

Fig. 2. Alteration of QRS waveform due to adenosine triphosphate iATPj
 The QRS interval becomes wider but the PR interval remains unchanged due to atrioventricular block by rapid ATP infusion iadenosine testj, which is diagnosed as having a functional accessory pathwayisj icitation from reference 27j.

@3.@WPWÇŒóŒQ‚Ì—\Œã

@Af‚ª—U”­‚³‚ꂽ–³ÇŒó‚ÌWPWÇŒóŒQ‚ðŽ¦‚µ‚½—á‚Ì‚¤‚¿C–ñ3”N‚ÌŒo‰ßŠÏŽ@’†‚ÉŽ©‘R”­ì‚ªoŒ»‚µ‚½8—á’†3—á‚ÉVf–”‚Í“Ë‘RŽ€‚ª”­¶‚µ‚½‚Æ‚¢‚¤•ñ‚ª‚ ‚è24jCŒ»Ý‚ÍCAf/AF‚ÌŠù‰‚ª‚ ‚éꇂÍS“Ë‘RŽ€‚̊댯ŒQ‚Æ‚¢‚¤”FŽ¯‚Å‚ ‚éBAf/AF‚ÌŠù‰ˆÈŠO‚̊댯ŒQ‚̊͌»ÝŠm—§‚³‚ê‚Ä‚¢‚È‚¢‚ªCKent‘©‚̇s«—LŒø•s‰žŠúiŠúŠOŽhŒƒ‚É‚æ‚Á‚Ä‹»•±‚ª¶‚¶‚È‚¢Å’·‚̘AŒ‹Šúj‚ª250–”‚Í270 msecˆÈ‰ºC•¡”•›“`“±˜HCEbsteinŠïŒ`‡•¹—á‚͈ê”Ê“I‚Ɋ댯ŒQ‚Æ‚³‚ê‚éBŽ©‘R”­ì‚ ‚é‚¢‚Í—U”­‚É‚æ‚éAfŽž‚ÌÅ’ZRRŠÔŠu‚ɂ‚¢‚Ä‚Í220C240–”‚Í250 msecˆÈ‰º‚ðŠëŒ¯ŒQ‚̊Ƃ·‚é‚à‚Ì‚ª‚ ‚éBEPS‚ÅCSŽº‰ž“š‚Ì‘‚¢Af‚âAVRT‚ª—U”­‚³‚ê‚éꇂâCAf‚ª—U”­‚³‚êKent‘©‡s«—LŒø•s‰žŠú‚ª300 msecˆÈ‰º‚ÌꇂàŠëŒ¯ŒQ‚Å‚ ‚é‚Æ‚Ì•ñ‚à‚ ‚é21jB

@WPWÇŒóŒQ‚Ì’†‚ÉCPSVTCAf/AF‚ðˆø‚«‹N‚±‚·ŠëŒ¯‚Í‚È‚¢‚Æ‚³‚ê‚éFVP‚É‚æ‚é‚à‚Ì‚ªŠÜ‚Ü‚ê‚Ä‚¢‚邱‚Æ‚ªŽw“E‚³‚ê‚Ä‚¢‚éBSuzuki‚ç‚ÍC–³ÇŒó‚©‚ÂQRS≦120 msec‚ÌWPWÇŒóŒQ30–¼i•½‹Ï”N—î12.7Îj‚ɃAƒfƒmƒVƒ“ƒeƒXƒg‚ðs‚¢CWPWÇŒóŒQi•›“`“±˜H‚É‹@”\‚ð—L‚·‚éj‚ÆFVPi•›“`“±˜H‚É‹@”\‚ð—L‚µ‚È‚¢j‚ÌŠÓ•Ê‚ðs‚Á‚½‚Æ‚±‚ëC7—ái23.3%j‚ªWPWÇŒóŒQC23—ái76.7%j‚ªFVP‚Å‚ ‚Á‚½BRosenbaum AŒ^‚ðŽ¦‚µ‚½—á‚Í6—á‘Sˆõi100%j‚ªWPWÇŒóŒQCBŒ^‚ðŽ¦‚µ‚½—á‚Í24—á’†23—Ⴊi96%j‚ªFVP‚Å‚ ‚Á‚½BBŒ^‚ðŽ¦‚µ‚½1—á‚ÌWPWÇŒóŒQ‚ÍCƒAƒfƒmƒVƒ“ƒeƒXƒg‚Å–¾‚ç‚©‚ÉWPWÇŒóŒQ‚Æ•ª‚©‚é‘å‚«‚ȃfƒ‹ƒ^”g‚ÆQRS„120 msec‚ðŽ¦‚µ‚Ä‚¢‚½B‚±‚ÌŒ‹‰Ê‚æ‚èCQRS≦120 msec‚ÌBŒ^‚ÍŠT‚ËFVP‚Å‚ ‚낤‚Æq‚ׂĂ¢‚é27jB

@‰Á‚¦‚Ĉȉº‚̂悤‚ÉlŽ@‚³‚ê‚Ä‚¢‚éB

@‡@@ƒgƒŒƒbƒhƒ~ƒ‹‰^“®•‰‰×S“d}‚ÍC–[Žº“`“±‚ªŒ°Ý‰»‚·‚邱‚Æ‚©‚çCƒfƒ‹ƒ^”g‚ª¬‚³‚­‚È‚èCQRS•‚ª‹·‚­‚È‚é‚Æ—\‘z‚³‚ê‚邪C—L—p‚Å‚Í‚È‚©‚Á‚½B

@‡A@ƒzƒ‹ƒ^[S“d}‚ðŽÀŽ{‚µCS–[ŠúŠOŽûk‚Ì”­¶‚âS””‚̕ω»‚ɉž‚¶QRS”g‚ÌŒ`‘Ԃ̕ω»‚ª”F‚ß‚ç‚ꂽꇂÍWPWÇŒóŒQ‚Æf’f‚Å‚«‚éB‚©‚ÂCS””‚ª­‚È‚­‚È‚Á‚½Žž‚ÍCWPWÇŒóŒQ‚Å‚ÍCƒfƒ‹ƒ^”g‚ª’˜–¾‚É‚È‚é‚Í‚¸‚Å‚ ‚éB

@Cohen‚ç‚É‚æ‚éì‹Æ•”‰ï‚ÍCWPWÇŒóŒQ‚ðŽ¦‚µ‚½8΂©‚ç21΂܂ł̎á”NŽÒ‚ɑ΂·‚éŽæˆµ‚¢iS“Ë‘RŽ€‚Ì—\–hj‚ɂ‚¢‚ÄŒ©‰ð‚ðŽ¦‚µCˆÈ‰º‚Ì’Ê‚è‚Æ‚È‚Á‚Ä‚¢‚é25jB

@‡@@–³ÇŒó‚ÌŠÔŒ‡«WPWÇŒóŒQ‚Ìꇂ͌o‰ßŠÏŽ@B

@‡A@–³ÇŒó‚ÌŒ°«WPWÇŒóŒQ‚Ìꇂ͉^“®•‰‰×ŒŸ¸‚ðs‚¢CPES‚ÌØ‹’‚ª‚È‚­‚È‚ê‚ÎŒo‰ßŠÏŽ@B‚»‚êˆÈŠO‚ÍEPS‚ðŽÀŽ{B

@‡B@EPS‚É‚æ‚èCSVT‚ª—U”­‚³‚ê‚ê‚΃AƒuƒŒ[ƒVƒ‡ƒ“‚Ì“K‰ž‚ª‚ ‚éB

@‡C@AfŽž‚ÌS“d}ã‚ÌÅ’ZRRŽžŠÔ‚ª250 msecˆÈ‰º‚ÌꇂÍCS“Ë‘RŽ€‚̉”\«‚ª‚‚¢‚̂ŃAƒuƒŒ[ƒVƒ‡ƒ“‚Ì“K‰ž‚ª‚ ‚èC250 msec‚æ‚è’·‚­CEPS‚É‚æ‚èSVT‚ª—U”­‚³‚ê‚È‚¢ê‡‚ÍŒo‰ßŠÏŽ@‚Å‚æ‚¢‚ªCSVT‚ð‹N‚±‚·‚ÆD‚Ü‚µ‚­‚È‚¢“Á’¥‚ª‚ ‚éŽÒi‚±‚±‚Å‚Í‘¼‚ÌSŽ¾Š³“™‚ð‡•¹‚µ‚Ä‚¢‚éŽÒ‚ð‘z’肵‚Ä‚¢‚éj‚̓AƒuƒŒ[ƒVƒ‡ƒ“‚ðs‚Á‚½•û‚ª—Ç‚¢B

@‰Á‚¦‚ĉߋŽ‚Ì•ñ‚Ì•ªÍ‚ðs‚¢CˆÈ‰º‚̂悤‚Éq‚ׂĂ¢‚éB

@‡@@‰Á—î‚Æ‚Æ‚à‚É•›“`“±˜H‚Ì‹@”\‚ª’ቺ‚·‚é‚Æl‚¦‚ç‚ê‚éB

@‡A@–³ÇŒó‚̬l‚ÌS“Ë‘RŽ€‚Ì”NŠÔ”­Ç—¦‚Í0%`0.45%‚Å‚ ‚Á‚½B

@‡B@‰^“®•‰‰×ŒŸ¸‚É‚æ‚éƒfƒ‹ƒ^”g‚ÌÁŽ¸‚ÍCKent‘©‚Ì’·‚¢‡s«—LŒø•s‰žŠú‚ÉŠÖ˜A‚µ‚Ä‚¢‚éB‚½‚¾‚µC‰^“®•‰‰×‚É‚æ‚Á‚ăfƒ‹ƒ^”g‚ªÁŽ¸‚·‚é‚Ì‚ÍŽå‚Æ‚µ‚ĬŽ™‚Å‚ ‚éB

@Fitzsimmons‚ç‚ÍCWPWÇŒóŒQ‚ðŽ¦‚µ‚½ŒR—pq‹ó]Ž–ŽÒ228–¼i•½‹Ï”N—î34.3Îj‚ɑ΂µ•½‹Ï22”NŠÔ’ÇÕ’²¸‚ðs‚Á‚½B‚»‚Ì‚¤‚¿1–¼‚¾‚¯‚ª“Ë‘RŽ€‚ð‹N‚±‚µ‚½i”NŠÔŽ€–S—¦0.02%jBusymptoms–”‚ÍSVTi‚±‚±‚Å‚Í3˜A”­ˆÈã‚ðŽw‚·jv‚ÌŠù‰—á‚Ì’ÇÕ’²¸’†‚ÌSVT‚Ì”­Ç‚Í46.3%i”NŠÔ”­Ç—¦2.0%jC–³ÇŒó—á‚ÌSVT‚ÌV‹K”­Ç‚Í15.3%i”NŠÔ”­Ç—¦0.7%j‚Å‚ ‚Á‚½BSVT‚ÌV‹K”­Ç‚ð”F‚ß‚½–³ÇŒó—á28–¼‚Ì‚¤‚¿19–¼‚ÉHDPi67.8%j‚ª”F‚ß‚ç‚ꂽ3jB

@Goudevenos‚ç‚ÍC–k¼•”ƒMƒŠƒVƒƒ‚ÅWPWÇŒóŒQ‚ðŽ¦‚µ‚½157–¼i•½‹Ï”N—î42.5Îj‚ɑ΂µ‚Ä•½‹Ï55ƒ–ŒŽi4.6”NjŠÏŽ@‚ðs‚Á‚½B‚»‚±‚É‚Í80–¼‚Ìsymptoms ibrief palpitationsj‚ªŠù‰—ð–”‚ÍŒo‰ßŠÏŽ@’†‚É”F‚ß‚ç‚ꂽ—á‚ÆC77–¼‚ÌŒo‰ßŠÏŽ@’†‚Ésymptoms‚Í”F‚ß‚ç‚ê‚È‚©‚Á‚½—Ⴊ“o˜^‚³‚ê‚Ä‚¢‚éB‚½‚¾Csymptoms‚ª”F‚ß‚ç‚ê‚È‚¢80–¼‚Ì‚¤‚¿CS“d}f’fŒã‚ɉ‚ß‚Äsymptoms‚ª”F‚ß‚ç‚ꂽ—á‚͂킸‚©3–¼‚µ‚©‚¢‚È‚©‚Á‚½5jB‚‚܂èC“–‰symptoms‚ª”F‚ß‚ç‚ê‚Ä‚¢‚È‚©‚Á‚½‚Ì‚ÍC77+3=80–¼‚Å‚ ‚Á‚½B•½‹Ï4.6”N‚ÌŒo‰ßŠÏŽ@‚Å3–¼‚ª”­Ç‚µ‚½‚±‚Æ‚©‚çC–³ÇŒó—á‚Ìsymptoms‚Ì”NŠÔ”­Ç—¦‚Í0.8%’ö“x‚Æ‚È‚éB‚È‚¨Csymptoms‚̉”­”N—î‚ÍŠT‚Ë40Ζ¢–ž‚Å‚ ‚Á‚½‚Æ•ñ‚µ‚Ä‚¢‚é5jB

@Munger‚ç‚ÍC–³ÇŒó‚ÌWPWÇŒóŒQ53–¼i•½‹Ï”N—î33Îj‚É537 patient-yearsŠÏŽ@‚ðs‚Á‚½‚Æ‚±‚ëC“Ë‘RŽ€‚Í”F‚ß‚ç‚ꂸC11–¼i”NŠÔ”­Ç—¦2.0%j‚Ésymptoms‚ª”F‚ß‚ç‚ꂽB‚»‚Ìsymptoms‚Ì“à–ó‚ÍC6–¼‚ÉtachycardiaC5–¼‚Élimited palpitation‚Å‚ ‚Á‚½B‚È‚¨Csymptoms‚ª”F‚ß‚ç‚ꂽ—á‚Ì•½‹Ï”N—î‚Í25΂ł ‚èC40ΈÈã‚Å‚Í”­Ç‚ª”F‚ß‚ç‚ê‚È‚©‚Á‚½‚Æ•ñ‚µ‚Ä‚¢‚é17jB

@4.@LGLÇŒóŒQ‚Ì—\Œã

@LGLÇŒóŒQ‚Å‚ÍCshort PRŽžŠÔ‚ð120 msecˆÈ‰º‚Æ‚µ‚½ê‡Cˆê”Êl‚Ì2`4%‚ª‚±‚ê‚ð–ž‚½‚·‚±‚Æ‚à•ñ‚³‚êCPRŽžŠÔ‚ÍŽ©—¥_Œo‚â–ò•¨‚̉e‹¿‚àŽó‚¯‚邱‚ÆC‚ ‚é‚¢‚ÍS“d}‚ð’Êí‚Ì‹L˜^‘¬“xi25 msecj‚Å‹L˜^‚·‚é‚ÆP”g‚Ì“dˆÊ‚ª’á‚­‚È‚¾‚ç‚©‚Å‚ ‚邱‚Æ‚©‚çC20 msec’ö“x‚Ì‘ª’èŒë·‚ª¶‚¶“¾‚邱‚Æ‚àŽw“E‚³‚ê‚Ä‚¢‚é9jB

@Nielsen‚ç‚ÍCCopenhagen General Practitionerfs Laboratory‚ÅŽQÆ‚Å‚«‚½11,087–¼‚Ì15ΈÈã‚ÅCAf‚ÌŠù‰‚Ì‚È‚¢‘ÎÛŽÒi•½‹Ï”N—î57ÎC‘¼‚ÌSŽ¾Š³‚ÌŠù‰‚àŠÜ‚Þj‚ɑ΂µC•½‹Ï5.7”NŠÔ‚Ì’ÇÕ’²¸‚ðs‚Á‚½B‚»‚ÌŒ‹‰ÊCPRŽžŠÔ‚ª’Zk–”‚͉„’·‚³‚ê‚ê‚΂³‚ê‚é‚Ù‚ÇC’j—‚Æ‚àJ‹Èü‚ð•`‚­‚悤‚ÉAf‚Ì”­Ç—¦‚ª‚‚܂邱‚Æ‚ðŽ¦‚µ‚½B‚»‚µ‚ÄC—«‚Ì121 msecˆÈ‰ºŒQi5% percentileˆÈ‰ºj‚ÍC’†‰›’lŒQi148-157 msecj‚É”ä‚×—LˆÓiŠëŒ¯—¦1.21j‚ÉAf‚Ì”­Ç‚Í‘½‚©‚Á‚½‚ªC’j«‚Ì129 msecˆÈ‰ºŒQi5% percentileˆÈ‰ºj‚ÍC’†‰›’lŒQi154-165 msecj‚É”ä‚ב½‚¢ŒXŒü‚ðŽ¦‚µ‚½‚ªC—LˆÓ‚Å‚È‚©‚Á‚½iŠëŒ¯—¦1.09jBAf‚ð”­Ç‚µ‚½—«‚Ì121 msecˆÈ‰ºŒQ‚ÉCƒfƒ‹ƒ^”g‚ð”F‚ß‚½‚Ì‚Í164–¼’†1–¼i0.6%j‚Å‚ ‚Á‚½B”NŠÔ”­Ç—¦‚ÍC—«‚Ì121 msecˆÈ‰ºŒQi•½‹Ï”N—î43Îj0.43%C—«‚Ì122-135 msecŒQi•½‹Ï”N—î47Îj0.39%C’j«‚Ì129 msecˆÈ‰ºŒQi•½‹Ï”N—î44Îj0.44%C’j«‚Ì166-179 msecŒQi³í”͈ÍC•½‹Ï”N—î55Îj0.71%‚Å‚ ‚Á‚½BÅ’Z‚ÌPRŽžŠÔ‚Í’j—‚Æ‚à104 msec‚Å‚ ‚Á‚½19jB

@Grossman‚ç‚ÍCPES‚ª‹^‚í‚ê‚é59–¼iƒfƒ‹ƒ^”g‚ª‹^‚í‚ê‚é—á15–¼Cƒfƒ‹ƒ^”g‚ª‚È‚¢—á44–¼C•½‹ÏPRŽžŠÔ110 msecj‚̃CƒXƒ‰ƒGƒ‹‹óŒR‚Ì‘€cŽmŒó•â¶‚ɃAƒfƒmƒVƒ“ƒeƒXƒg‚ðŽÀŽ{‚µC‚·‚ׂĂ̌ó•â¶‚É–¾‚ç‚©‚È•›“`“±˜H‚ð”F‚߂銌©‚ª”F‚ß‚ç‚ꂸC•½‹Ï35.4ƒ–ŒŽŠÏŽ@‚ðs‚Á‚½‚ªˆÙí‚Í”F‚ß‚È‚©‚Á‚½‚Æ•ñ‚µ‚Ä‚¢‚é6jB

@C.@AVT‚ÌŽ¡—Ã

@–{ŒŸ“¢‚Ŏ戵‚¤Ž¾Š³iTable 1j‚ÌŽ¡—Â͌´‘¥ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Å‚ ‚éBƒAƒuƒŒ[ƒVƒ‡ƒ“‚ÉŠÖ‚·‚éÚׂÍCƒAƒuƒŒ[ƒVƒ‡ƒ“ƒKƒCƒhƒ‰ƒCƒ“‹y‚Ñ”ñ–ò•¨—Ö@ƒKƒCƒhƒ‰ƒCƒ“‚É‹LÚ‚³‚ê‚Ä‚¨‚èCAVT‚̪Ž¡‚ªŠú‘Ò‚Å‚«‚鎡—Ö@‚Å‚ ‚é21,23jBTable 2‚É‚ÍC‚±‚ê‚çƒKƒCƒhƒ‰ƒCƒ“‚É‚¨‚¯‚éƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì„§“x‚ð‚Ü‚Æ‚ß‚½BEPSiƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚ÌŒø‰Ê”»’è‚ðŠÜ‚Þj‚ÉŠÖ‚·‚éÚׂÍCEPSƒKƒCƒhƒ‰ƒCƒ“‚É‹LÚ‚³‚ê‚Ä‚¢‚é21jB‚È‚¨C‚±‚ê‚ç‚ÌŽè‹Z‚ð‚±‚±‚Å‚ÍuƒJƒe[ƒeƒ‹ˆ’uv‚Æ‚¢‚¤‚±‚Æ‚Æ‚·‚éB

@AVNRT‹y‚ÑWPWÇŒóŒQiAVRTj‚̃AƒuƒŒ[ƒVƒ‡ƒ“‚ÌŽè‹Z‚Í‚Ù‚ÚŠm—§‚³‚ꂽ‚Æ‚³‚ê‚é31jBLGLÇŒóŒQ‚ÍC‚»‚Ìf’f‚É‚ÍPSVTCAf/AF‚ÌŠù‰‚ð—L‚·‚é•K—v‚ª‚ ‚邱‚Æ‚©‚çCÇó‚ð—L‚·‚éꇂ̓Jƒe[ƒeƒ‹ˆ’u‚Ì“K‰ž‚Æl‚¦‚ç‚ê‚邪Cshort PRŽžŠÔ‚Ì‚Ý‚Å‚±‚ê‚ç‚ÌŠù‰‚ð—L‚µ‚È‚¢—á‚É‚ÍCˆê”Ê“I‚É“K‰ž‚³‚ê‚È‚¢‚Æ‚³‚ê‚Ä‚¢‚é30jB‚µ‚©‚µCshort PRŽžŠÔ—á‚ÅAf“™‡•¹Žž‚ÉVf”­Ç‚ª•ñ‚³‚ê‚Ä‚¢‚邱‚Æ‚Í’ˆÓ‚ð—v‚·‚é21jB

Table 2.@Advisability of catheter ablation in case of atrioventricular tachyarrhythmias.
–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[•p” WPWÇŒóŒQ
ƒNƒ‰ƒXI 1.@Ž¸_‚È‚Ç‚Ìd“Ä‚ÈÇó‚âŒyÇó‚Å‚àQOL‚Ì’˜‚µ‚¢’ቺ‚𔺂¤•p””­ì‚ÌŠù‰‚ª‚ ‚éê‡ 1.@¶–½‚Ɋ댯‚ð‹y‚Ú‚·ŠëŒ¯«‚ª‚ ‚éC‚Ü‚½‚ÍŽ¸_‚È‚Ç‚Ìd“Ä‚ÈÇó‚𔺂¤•p–¬«S–[ד®‚⑼‚ÌS–[«•p–¬«•s®–¬‚ª‚ ‚éê‡
2.@•p””­ì‚ª‚ ‚èC–ò•¨Ž¡—Â̗L–³‚ÉŠÖ‚í‚炸Š³ŽÒ‚ªƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŠó–]‚·‚éê‡ 2.@•›“`“±˜H‚ð‰î‚µ‚½•p””­ì‚ª‚ ‚èC’ZŽžŠÔ‚ÅŽ©‘R’âŽ~‚µ‚È‚¢CÇó‚𔺂¤C•p“x‚ª‘½‚¢C‚È‚Ç‚Ìê‡
3.@•›“`“±˜H‚ð‰î‚µ‚½•p””­ì‚Í‚È‚¢‚ªCƒnƒCƒŠƒXƒNŒQ‚ÅCŒö‹¤Œð’Ê‹@ŠÖ‚̉^“]Žè‚È‚ÇC‹Æ–±“à—e‚ªŠ³ŽÒˆÈŠO‚Ìl–½‚ÉŠÖ‚í‚é‰Â”\«‚ª‚ ‚éê‡
ƒNƒ‰ƒXIIa 1.@•p””­ì‚ÌS“d}‚ªŠm”F‚³‚ê‚Ä‚¢‚銳ŽÒ‚ÅC“d‹C¶—ŒŸ¸‚Å•p”‚ª—U”­‚³‚ꂸ“ñd–[ŽºŒ‹ß“`“±˜H‚Ì‚Ý‚ª”F‚ß‚ç‚ê‚½ê‡ 1.@•›“`“±˜H‚ð‰î‚µ‚½•p””­ì‚Í‚È‚­CƒnƒCƒŠƒXƒNŒQ‚Å‚à‚È‚¢‚ªCS–[ד®”­Ç‚̉”\«‚È‚Ç‚ðl—¶‚µ‚ÄŠ³ŽÒ‚ªƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŠó–]‚·‚éê‡
2.@‘¼‚Ì•p”‚ɑ΂·‚é“d‹C¶—ŒŸ¸‚Ü‚½‚̓Jƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Ã’†‚É‹ô‘R—U”­‚³‚ꂽ–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ•p” 2.@•p””­ì‚ð”F‚ß‚Ä‚àÇ󂪌y”÷‚ÅC’ZŽžŠÔ‚ÅŽ©‘R’âŽ~‚µC•p“x‚à‚Ü‚ê‚Èê‡
ƒNƒ‰ƒXI:—L‰v‚Å‚ ‚é‚Æ‚¢‚¤ª‹’‚ª‚ ‚èC“K‰ž‚Å‚ ‚邱‚Æ‚ªˆê”Ê‚É“¯ˆÓ‚³‚ê‚Ä‚¢‚éBƒNƒ‰ƒXIIa:—L‰v‚Å‚ ‚é‚Æ‚¢‚¤ˆÓŒ©‚ª‘½‚¢‚à‚ÌBiƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì“K‰ž‚ÆŽè‹Z‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“‹y‚Ñ•s®–¬‚Ì”ñ–ò•¨Ž¡—ÃKƒCƒhƒ‰ƒCƒ“i2011”N‰ü’ù”Åj‚æ‚èˆø—pj

III.@q‹óˆãŠw“I’mŒ©

@q‹óˆãŠw“I’mŒ©‚Å—L—p‚È‚à‚Ì‚ÍCˆê”Ê“I‚É‚Í–¯ŠÔq‹óˆãŠwƒ}ƒjƒ…ƒAƒ‹iManual of Civil Aviation Medicine: –¯ŠÔq‹ó‚̈ãŠw•]‰¿‚ÉŠÖ‚·‚é•W€“I‚ȃ}ƒjƒ…ƒAƒ‹CŽå‚Æ‚µ‚ĉ¢B‚Ìq‹ó“–‹Ç‚ÌŒ¤‹†ŽÒ‚ªì¬jCq‹óg‘ÌŒŸ¸ˆãƒKƒCƒhiGuide for Aviation Medical Examiners:•Ä‘‚É‚¨‚¯‚éq‹óg‘ÌŒŸ¸ƒ}ƒjƒ…ƒAƒ‹jC•Ä‹óŒRƒEƒF[ƒo[ƒKƒCƒhiAir Force Waiver Guide:•Ä‹óŒR‚É‚¨‚¯‚éƒEƒF[ƒo[R¸\¿‚Ì‚½‚߂̃}ƒjƒ…ƒAƒ‹jC•ÄŠCŒRƒEƒF[ƒo[ƒKƒCƒhiU. S. Navy Aeromedical Reference and Waiver Guide:•ÄŠCŒR‚É‚¨‚¯‚éq‹óg‘ÌŒŸ¸‚Ì•û–@‹y‚уEƒF[ƒo[R¸\¿‚Ì‚½‚߂̃}ƒjƒ…ƒAƒ‹j“™‚̃}ƒjƒ…ƒAƒ‹CRaymanfs Clinical Aviation Medicine“™‚Ì‹³‰È‘C˜_•¶“™‚Å‚ ‚éB‚±‚ê‚ç‚ðŒŸõ‚µ‚½Œ‹‰ÊC•]‰¿‹y‚Ñ”»’è–@쬂ɗLŒø‚È‹Lq‚Ì‚Ý‚ðˆÈ‰º‚Éq‚ׂéB

@‚È‚¨C‘“à‚Ì‹K‘¥‚àŒŸ“¢‚É•K—v‚Å‚ ‚邽‚ßC‚±‚±‚Åq‚ׂéB

@A.@–¯ŠÔq‹óˆãŠwƒ}ƒjƒ…ƒAƒ‹15j

@AVNRT‚ÍC”­ì‚͈궊U‚É‚¨‚¢‚ÄÄ”­‚·‚éŒXŒü‚ª‚ ‚èCŠmŽÀ‚ÉŠ®‘S‚É—}§‚·‚邱‚Æ‚ª‚Å‚«‚È‚¢‚½‚ßC’ÊíC“K«‚ðŒ‡‚­B—áŠO‚Æ‚µ‚ÄC’x“`“±˜H‚ÌCü‚ðŽó‚¯‚ÄCEPS‚Å—U”­‚³‚ê‚È‚¯‚ê‚ÎC“K«‚ð—L‚·‚é‚Æ‚Å‚«‚éi1.5.23‚Ì€jB

@‰‚ß‚ÄWPWÇŒóŒQ‚ðŽ¦‚µ‚½ê‡C“K«‚ðŒ‡‚­‚Æ‚·‚ׂ«‚Å‚ ‚éB•s®–¬‚ÌŠù‰‚ª‚È‚­C¸¸‚ɈÙ킪‚È‚¯‚ê‚ÎC•¡À‹@i2–¼ˆÈã‚Ì‘€cŽm‚ª‘€c‰Â”\‚Èq‹ó‹@j‚Ì‹Æ–±ðŒ‚ð•t‚µ‚Ä“K«‚ðl—¶‚·‚邱‚Æ‚ª‚Å‚«‚éi1.5.27‚Ì€jB

@–³§ŒÀ‚Ì“K«‚ÉŠÖ‚µ‚Ä‚ÍCEPS‚Å—U“±«SVT‚ð”F‚ß‚È‚¢‚±‚ÆC‹y‚Ñ•›“`“±˜H—LŒø•s‰žŠú‚ª300 msec‚æ‚è‘å‚«‚¢‚±‚Æ‚ÌØ–¾‚ª•K—v‚Å‚ ‚éBƒŠƒGƒ“ƒgƒŠ[«•s®–¬‚ÌŠù‰—ð‚ª‚ ‚éê‡C•›“`“±˜H‚̃AƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚臊i‚ª‰Â”\‚Å‚ ‚éi1.5.28‚Ì€jB

@B.@•Ä‹óŒRƒEƒF[ƒo[ƒKƒCƒh1j

@Ç󂪂 ‚é‚à‚Ì‚Í“K«‚ðŒ‡‚­B3˜A”­ˆÈã‚Ì㎺ŠúŠOŽûk‚ÍÚׂȕ]‰¿‚ðs‚¤‚±‚Æ‚Æ‚È‚Á‚Ä‚¢‚éiSupraventricular Tachycardia‚ÌÍjB

@AVNRT‚ÍC‘€cŽmŒó•â¶‚Å‚àŒ»–ð‘€cŽm‚Å‚àCƒEƒF[ƒo[R¸‰Â”\‚Å‚ ‚éiCatheter Ablation of Tachyarrhythmias and/or Pre-Excitation iWPWj‚ÌÍjB

@WPWÇŒóŒQi–³ÇŒó‚àŠÜ‚Þj‚Í•s“K‡‚Å‚ ‚éB‘€cŽmŒó•â¶‚ł̓EƒF[ƒo[R¸‰Â”\‚Å‚ ‚邪CEPS‚ÌŽÀŽ{‚ª•K—v‚Æ‚È‚éB‚È‚¨CŒ»–ð‘€cŽm‚ÉŠÖ‚µ‚Ä‚ÍCEPS‚ÉŠÖ‚µ‚ÄŒ¾‹y‚³‚ê‚Ä‚¢‚È‚¢iWolff-Parkinson-White iWPWj and Other Pre-Excitation Syndromes‚ÌÍjB

@SVT‚ÉŠÖ‚µCƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ªs‚í‚ê‚Ä‚¢‚È‚¢ŒÀ‚èCÇó‚𔺂¤‚à‚Ì‚ÍŒ´‘¥“I‚É“K«‚ðŒ‡‚­BÄ”­‚µ‚½Ž‘±«SVTi‚±‚±‚Å‚Í10•ªˆÈ㑱‚­SVT‚ðŽw‚·j‚Í“K«‚ðŒ‡‚­BƒRƒ“ƒgƒ[ƒ‹‚·‚邽‚ß‚ÉR•s®–¬–ò‚ª•K—v‚È‚à‚Ì‚Í“K«‚ðŒ‡‚­iSupraventricular Tachycardia‚ÌÍjB

@C.@•ÄŠCŒRƒEƒF[ƒo[ƒKƒCƒh29j

@Çó‚Ì‚ ‚éWPWÇŒóŒQ‚Í“K«‚ðŒ‡‚­B–³ÇŒó‚ÌWPWS“d}”gŒ`‚ª‚ ‚ê‚ÎCEPS‚ðŠÜ‚Þ•]‰¿‚ª•K—v‚ÅCˆÙ킪‚È‚¯‚ê‚ÎCƒEƒF[ƒo[R¸‰Â”\‚Å‚ ‚éBEPS‚Å•s®–¬‚ª—U”­‚³‚ꂽꇂÍCƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðs‚¢C“¯‚¶•û–@‚Å—U”­‚³‚ê‚È‚¢‚±‚Æ‚ðŽ¦‚·•K—v‚ª‚ ‚éBService Group 3i•¡À‹@ŒÀ’è‘€cŽmj‚Å‚ ‚ê‚ÎC6ƒ–ŒŽŠÔ‚ÌŒo‰ßŠÏŽ@‚ÌŒã‚ɃEƒF[ƒo[R¸\¿‰Â”\‚Æ‚È‚éBService Group 1i‹Æ–±ðŒ‚ªŒÀ’肳‚ê‚È‚¢‘€cŽmj“™‚Å‚ ‚ê‚ÎC6ƒ–ŒŽŠÔ‚ÌŒo‰ßŠÏŽ@ŒãCÄ”­“™‚ð‹N‚±‚³‚È‚¢‚±‚Æ‚ðØ–¾‚·‚é‘—Þ‚ð•t‚µ‚ăEƒF[ƒo[R¸\¿‰Â”\‚Å‚ ‚éBÇó‚𔺂¤WPWÇŒóŒQ‚âLGLÇŒóŒQ‚ŃEƒF[ƒo[R¸‚ðŽó‚¯‚é‚É‚ÍCƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª•K—v‚Å‚ ‚éB

@ƒfƒ‹ƒ^”g‚𔺂í‚È‚¢very short PRŽžŠÔ iPRƒ100 msecj‚Í”ñNP“IS•]‰¿‚ňÙ킪‚È‚¯‚ê‚ΓK‡‚Å‚ ‚邪CˆÙ킪‚ ‚ê‚Εs“K‡‚ÅCEPS–”‚̓AƒuƒŒ[ƒVƒ‡ƒ“‚ª•K—v‚Æ‚È‚éB

@•s®–¬‚âÇó‚𔺂í‚È‚¢short PRŽžŠÔ i≧100 msecj ‚Í“K«‚ð—L‚·‚éBˆÈŒãC•]‰¿‚Í•s—v‚Å‚ ‚éi3.19 Pre-excitation Syndromes‚ÌÍjB

@D.@‚킪‘‚Ì‘“yŒð’ÊÈq‹ó‹ÇiˆÈ‰ºuq‹ó‹Çv‚Æ‚¢‚¤j‚Ì‹K‘¥2j

@’Ê’Bu’²—¥ˆÙí‚̎戵‚¢‚ɂ‚¢‚Äv‚Å‚ÍCˆÀÃŽžS“d}‚ÅCSŽº‹NŒ¹‚Å‚ ‚ê㎺‹NŒ¹‚Å‚ ‚ê2”­ˆÈã‚ÌŠúŠOŽûk‚ª‚ ‚Á‚½ê‡‚ɂ̓zƒ‹ƒ^[S“d}‚ðs‚¤‚±‚Æ‚Æ‚È‚Á‚Ä‚¨‚èC
@‡@@5,000”­/“úˆÈã‚Ì㎺ŠúŠOŽûkB
@‡A@SVTi10˜A”­ˆÈã‚©‚ÂS””170/bpmˆÈãC‚Ü‚½‚Í30•bˆÈ㎑±‚·‚é‚à‚Ìj
@‚Ì‚Ç‚¿‚ç‚©”F‚ß‚ç‚ê‚ê‚Εs“K‡‚Å‚ ‚éB

@ƒEƒF[ƒo[R¸‚É’ño‰Â”\‚ÈŒo‰ßŠÏŽ@ŠúŠÔ‚͈ȉº‚Ì’Ê‚è‚Å‚ ‚éB

@‡@@WPWÇŒóŒQ‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã:6ƒ–ŒŽ

@‡A@WPWÇŒóŒQ‚É‚æ‚é•p””­ìŠù‰:•p””­ì‚ÌoŒ»‚Ì‚È‚¢ó‘Ô‚Å6ƒ–ŒŽ

@E.@q‹ó‹Ç‚Ì‹K’è‚ÉŠî‚¢‚½Fitzsimmons‚ç‚Ì•ñ‚̉ðÍ

@SVT‚Æ‚Í10˜A”­ˆÈã‚ðŽ¦‚·‚à‚Ì‚ðŽw‚·‚悤‚Å‚ ‚邪28jC–¾Šm‚È’è‹`‚ª‚³‚ê‚Ä‚¢‚È‚¢B‰äX‚ÍCq‹ó‹Ç‚Ì‹K’è2j‚ðŽQl‚ÉCHDP‚𗈂·‚Æl‚¦‚ç‚ê‚éuq‹ó‹ÇŠî€v‚ðˆÈ‰º‚Ì‚¢‚¸‚ê‚©‚ð–ž‚½‚·‚±‚Æ‚Æ’è‹`‚µ‚½B

@‡@@㎺«‚Ì•s®–¬‚ª10˜A”­ˆÈã‚©‚ÂS””170 bpmˆÈã‚ðŽ¦‚µ‚½‚à‚ÌB

@‡A@㎺«‚Ì•s®–¬‚ª30•bˆÈ㎑±‚µ‚½‚à‚ÌiAf/AF/AT‚𜂭jB

@Fitzsimmons‚ç•ñ3j‚Ì–³ÇŒó—á‚É‚¨‚¯‚éV‹K”­Ç—á‚Ì‚¤‚¿SVTi3˜A”­ˆÈãj‚ª‹L˜^‚³‚ꂽ18—á‚ð‰ðÍ‚·‚é‚ÆCq‹ó‹ÇŠî€‚ð–ž‚½‚·‚à‚Ì‚Í15—ái83.3%j‚Å‚ ‚Á‚½B–³ÇŒó—á‚ÌSVT‚ÌV‹K”­Ç‚Í15.3%i”NŠÔ”­Ç—¦0.7%j‚Æ•ñ‚³‚ê‚Ä‚¢‚é‚Ì‚ÅCq‹ó‹ÇŠî€‚ð–ž‚½‚·‚à‚Ì‚Í”NŠÔ0.6%’ö“x‚Æ—\‘z‚³‚ê‚éB‚È‚¨C–³ÇŒó—á‚É‚¨‚¢‚ÄCŒo‰ßŠÏŽ@’†‚ÉWPWÇŒóŒQ‚ªÁ‚¦‚½—áiŠÔŒ‡«WPWÇŒóŒQj‚ÍC‚»‚¤‚Å‚È‚¢—á‚É”ä‚ׂÄC—LˆÓ·‚ª‚È‚©‚Á‚½‚ªCSVT‚Ì”­Ç‚ª­‚È‚©‚Á‚½i8.7%‘Î23%jB–³ÇŒó‚ÌŠÔŒ‡«WPWÇŒóŒQ‚Ì—á‚ð‰ðÍ‚·‚é‚ÆCSVTi3˜A”­ˆÈãj‚ÌV‹K”­Ç‚Í”NŠÔ0.2%’ö“xCq‹ó‹ÇŠî€‚ð–ž‚½‚·‚à‚Ì‚à”NŠÔ0.2%’ö“x‚Æ—\‘z‚³‚ê‚éB

@F.@1%ƒ‹[ƒ‹

@Œ»Ýu1%ƒ‹[ƒ‹v‚ÉŠî‚¢‚½Šm—¦˜_“I‚È“K«”»’è‚ðs‚¤‚±‚Æ‚ªCq‹óˆãŠwã‚̃ŠƒXƒN•]‰¿‚ÌŠî–{“I‚Èl‚¦•û‚Æ‚È‚Á‚Ä‚¢‚éB•¡À‹@‚Ì‹Æ–±‚Ì‘€cŽm‚ª‹@”\‘rŽ¸‚ð‹N‚±‚µ‚½ê‡‚ð‘z’肵CˆÈ‰º‚ÌŒŸ“¢‚©‚ç‚»‚Ì’l‚Í“±‚«o‚³‚ꂽB

@‰ß‹Ž‚ÌŽ–ŒÌ‚ÌŒŸ“¢‚©‚ç’vŽ€“I‚ÈŽ–ŒÌ‚Í107ŽžŠÔ‚É1‰ñ‚ÌŠ„‡‚Å‹N‚±‚é‚Æ‚³‚ê‚Ä‚¢‚éB‚»‚Ì“à1/10‚ªl“I—vˆö‚ÅC‚³‚ç‚É‚»‚Ì1/10‚ª”òs’†‚Ì‹@”\‘rŽ¸‚É‚æ‚éB‚‚܂è109ŽžŠÔ‚É1‰ñˆÈã‚Ì•p“x‚Ì‹@”\‘rŽ¸‚ð‹N‚±‚µ‚Ä‚Í‚È‚ç‚È‚¢‚Æ‚³‚ê‚éB”òsŽžŠÔ‚Ì‚¤‚¿“Á‚Ɋ댯‚ÈŠúŠÔ‚ÍC—£—¤‚Æ’…—¤‚ÌŠÔ‚ÅC‚»‚ê‚ç‚Í‘S”òsŽžŠÔ‚Ì10%‚Ì‚Ý‚Å‚ ‚éB‚±‚̊댯‚ÈŽžŠÔ‚É‚¨‚¢‚Ä‘€c’†‚Ì‘€cŽm‚É‹@”\‘rŽ¸‚ª‹N‚±‚Á‚½‚Æ‚µ‚Ä‚àC‰ß‹Ž‚ÌŒŸ“¢‚©‚瑼‚Ì‘€cŽm‚ª100‰ñ‚Ì‚¤‚¿99‰ñ‚܂ł͈À‘S‚É‘€c‚ðŒð‘ã‚Å‚«‚é‚Æ‚³‚ê‚éB‚æ‚Á‚ÄC1/1,000C‚·‚È‚í‚¿•¡À‹@‚Ì‹Æ–±‚Ìê‡C106ŽžŠÔ‚É1‰ñˆÈã‚Ì•p“x‚ÌŽ–ŒÌ‚Í‹N‚±‚·‚ׂ«‚Å‚Í‚È‚¢‚±‚Æ‚Æ‚È‚éB1”NŠÔ‚Í8,760ŽžŠÔ‚Å‚ ‚邪C10,000i104jŽžŠÔ‚Æ‚µ‚Äl‚¦‚é‚ÆC”NŠÔ‚Ì‹@”\‘rŽ¸‚ÌŠm—¦‚ªŠT‚Ë1%ˆÈ‰º‚Å‚ ‚ê‚ÎC‹@”\‘rŽ¸‚É‚æ‚鎖ŒÌ‚ðŠm—¦˜_ã‹–—e‚Å‚«‚邱‚Æ‚É‚È‚é15jB

@‚±‚ê‚Í–¯ŠÔq‹ó‚É‚¨‚¯‚é•¡À‹@‚Ì‹Æ–±‚ÅŒ¾‚¦‚邱‚Æ‚Å‚ ‚é‚Ì‚ÅC’PÀ‹@Ží‚⎩‰q‘à‚Ì‚G‹@Ží‚É‚Í“–‚Ä‚Í‚Ü‚ç‚È‚¢B‚½‚¾‚µCŽ©‰q‘à‚Å‚à—A‘—‹@“™‚Ì•¡À‹@‚Ì‹Æ–±‚ɂ‚¢‚Ä‚ÍCŠî–{“I‚É1%ƒ‹[ƒ‹‚ÉŠî‚¢‚ăŠƒXƒN•]‰¿‚·‚邱‚Æ‚ª“K“–‚Æl‚¦‚éB

@‚È‚¨C–³§ŒÀi•t‘ÑðŒ‚È‚µj‚Ì“K«‚ð”F‚ß‚éꇂÍCŒ’íŽÒ‚Æ“¯“™‚Ì‹@”\‘rŽ¸‚ÌŠm—¦‚Æl‚¦‚ç‚ê‚鎞‚Å‚ ‚낤B

IV.@’mŒ©‚ÉŠî‚¢‚½“K«‚Ìl‚¦•û

@A.@q‹ó‹ÇŠî€‚ÉŠî‚¢‚½“K«‚Ìl‚¦•û

@Fitzsimmons‚ç‚Ì•ñ3j‚ÅCuSVTi‚±‚±‚Å‚Í3˜A”­ˆÈã‚ðŽw‚·jv‚ªŠÏŽ@‚³‚ꂽ‚à‚Ì‚¤‚¿C67.8%‚ÉHDP‚ª”F‚ß‚ç‚êC83.3%‚Éq‹ó‹ÇŠî€‚ð–ž‚½‚µ‚½‚±‚Æ‚©‚çCHDP‚ð”F‚ß‚éó‘Ô‚Æ‚¢‚¤‚à‚Ì‚ÍCq‹ó‹ÇŠî€–”‚Í‚»‚ê‚æ‚舫‚¢•a‘Ô‚ÌSVT‚ª‘¶Ý‚·‚é󋵂ł ‚é‚Æl‚¦‚ç‚ê‚éB

@AVT‚É‚æ‚éuŠ®‘S‚Èv‹@”\‘rŽ¸‚ª‹N‚±‚肤‚é‚Ì‚ÍCVT/VF‚ðŽä‹N‚·‚é‚悤‚È•a‘Ô‚ª‚ ‚éꇂł ‚èC‚±‚ê‚ç‚Ì”NŠÔ”­Ç—¦‚ª1%‚ð’´‚¦‚éꇂ͓K«‚ðŒ‡‚­B‰Á‚¦‚ÄCHDP‚ð”F‚ß‚éó‘Ô‚ÍCˆÀ‘S‚Èq‹ó‹Æ–±‚ðs‚¤‚±‚Æ‚Í‚Å‚«‚È‚¢‚±‚Æ‚©‚çC“¯—l‚ÉHDP‚Ì”NŠÔ”­Ç—¦‚ª1%‚ð’´‚¦‚éꇂ͓K«‚ðŒ‡‚­‚Æ‚·‚é‚Ì‚ª“K“–‚Æl‚¦‚ç‚ê‚éB

@“®œ§C‚ß‚Ü‚¢CŽ¸_“™‚ÌŽ©ŠoÇ󂪂 ‚ê‚ÎHDP‚ª‚ ‚é‚Æ‚¢‚¦‚邪C‘€c‹Æ–±‚ªs‚¦‚È‚­‚È‚é‰Â”\«‚©‚ç\¿ŽÒ‚ª“KØ‚É\‚µ‚È‚¢ê‡‚à‚ ‚蓾‚éB‚»‚±‚ÅCHDP‚ÌŽ©ŒÈ\‚ɉÁ‚¦Cƒzƒ‹ƒ^[S“d}“™‚Ì‹qŠÏ“I‚ÈŒŸ¸Œ‹‰Ê‚©‚çHDP‚Ì—L–³‚ð„’è‚·‚é•K—v‚à‚ ‚éB”ñí‚É¢“ï‚È“_‚ÍC‚Ç‚Ì’ö“x‚ÌSVT‚ðuHDP‚ª‚ ‚év‚Æ’è‹`‚·‚é‚©‚Å‚ ‚邪Cã‹L‚µ‚½‚悤‚ÉCq‹ó‹ÇŠî€‚ªHDP‚ð”F‚߂鉊ú‚Ìó‘Ô‚Æl‚¦‚Ä‚æ‚¢‚Å‚ ‚낤B‚È‚¨CWPW ÇŒóŒQ‹y‚ÑLGL ÇŒóŒQ‚ÍAf‚̊댯ˆöŽq‚Å‚ ‚邱‚Æ‚©‚çCAf‚Ì“¯—l‚Ì•a‘Ô‚Å‚ ‚éAF/AT‚à‰Á‚¦‚ÄHDP‚Æ‚·‚ׂ«‚Å‚ ‚éB

@ˆÈã‚ÌŒŸ“¢‚©‚çCˆÈ‰º‚Ì‚¢‚¸‚ê‚©‚ÌꇂÍuHDPv‚Æ”»’f‚µ‚Ä‚æ‚¢‚Å‚ ‚낤B

@‡@@Œ´Ž¾Š³‚ÉŠî‚­HDP‚ª‚ ‚éê‡B

@‡A@WPW ÇŒóŒQ–”‚ÍLGL ÇŒóŒQ‚É‚¨‚¢‚ÄAf/AF/AT‚ÌŠù‰‚ª‚ ‚éê‡B

@‡B@ã‹L‚ª•s–¾‚ÈꇂÍCŒo‰ßŠÏŽ@’†i‚»‚ÌŠúŠÔ‚ÌŒŸ“¢‚͈ȉº‚Ås‚¤j‚Éq‹ó‹ÇŠî€‚ð”F‚ß‚½ê‡B

@q‹ó‹Ç‹y‚Ñq‹óŽ©‰q‘à‚Ì‹K’è‚É‹LÚ‚³‚ê‚Ä‚¢‚éuŽ‘±«‚Ì㎺•p”/•p””­ì/”­ì«•p”v‚Í”ñí‚ÉžB–†‚È•\Œ»‚Å‚ ‚邪Cã‹L€–Ú‚ð–ž‚½‚·‚à‚Ì‚Æ‚·‚ê‚΂悢‚Å‚ ‚낤B

@B.@‰‰ñ•]‰¿

@‰‚ß‚ÄAVT‚Ì•]‰¿‚ðs‚¤ê‡CŠî‘bŽ¾Š³“™‚ÌÚׂȕ]‰¿‚ðs‚¤•K—v‚ª‚ ‚éB’ÊíuƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸iSƒGƒR[ŒŸ¸Cƒzƒ‹ƒ^[S“d}CƒgƒŒƒbƒhƒ~ƒ‹‰^“®•‰‰×S“d}ŒŸ¸“™jv‚ðŽÀŽ{‚µCŠî‘bŽ¾Š³“™‚ª‹^‚í‚ꂽꇂɂ͊펿“IS•]‰¿iŠjˆãŠwŒŸ¸CŠ¥“®–¬‘¢‰eCS‘ŸMRI“™j“™‚ðŽÀŽ{‚·‚邱‚Æ‚Æ‚È‚éBˆÈã‚Ì•]‰¿‚É‚ÄC—Õ°ã—LˆÓ‚Ȋ펿“ISŽ¾Š³“™‚̈Ù킪”F‚ß‚ç‚ê‚È‚¢ê‡‚ÍuŠî‘bŽ¾Š³“™‚ª”F‚ß‚ç‚ê‚È‚¢v‚Æ‚¢‚¤‚±‚Æ‚É‚È‚éBŠî‘bŽ¾Š³“™‚ª”F‚ß‚ç‚ꂽꇂÍC‚»‚ÌŽ¡—Ó™‚ðs‚¤‚ׂ«‚Å‚ ‚éB

@Šî‘bŽ¾Š³“™‚ÌŽ¡—ÃCƒJƒe[ƒeƒ‹ˆ’uC–ò•¨Ž¡—Ö”‚ÍŒo‰ßŠÏŽ@“™‚É‚ÄCÇó“™‚ªˆÀ’肵‚½ê‡‚ÍCŒo‰ßŠÏŽ@ŠúŠÔ‚ðÝ‚¯Cƒzƒ‹ƒ^[S“d}“™‚ÅÄ”­“™‚ª‚È‚¢‚±‚Æ‚ÌŠm”F‚ðs‚¤BˆÈã‚̈ê˜A‚Ì—¬‚ê‚ðC‚±‚±‚Å‚Íu‰‰ñ•]‰¿v‚Æ‚¢‚¤‚±‚Æ‚Æ‚·‚éB

@C.@Ž¡—Ã

@AVT‚̃}ƒNƒƒŠƒGƒ“ƒgƒŠ[‚Ì•a‘Ô‚©‚çC“Á‚É‘€cŽm‚ɑ΂µ‚Ă̓AƒuƒŒ[ƒVƒ‡ƒ“‚É‚¨‚¯‚骎¡‚̉”\«‚ðl—¶‚·‚ׂ«‚Å‚ ‚éB

@q‹ó‹Ç‚̃EƒF[ƒo[R¸‚É‚¨‚¢‚ÄCWPWÇŒóŒQ‚ŃAƒuƒŒ[ƒVƒ‡ƒ“‚ðs‚Á‚½ê‡‚ÍC6ƒ–ŒŽ‚ÌŒo‰ßŠÏŽ@‚Ì‹K’è‚ðÝ‚¯‚Ä‚¢‚é2jBŒ»Ý‚Ì‚Æ‚±‚ëC‚±‚ÌŠúŠÔ‚É‚Ä•s‹ï‡‚ª¶‚¶‚Ä‚¢‚È‚¢‚½‚ߑÓ–‚Æl‚¦‚ç‚ê‚邪CŒo‰ßŠÏŽ@‚ð6ƒ–ŒŽ‚Æ‚µ‚½–¾Šm‚Ȫ‹’‚ª‚È‚¢‚½‚ßC¡Œã–¾Šm‚Ȫ‹’‚ª‚ ‚ê‚΂»‚ê‚É]‚Á‚Ä•ÏX‚·‚ׂ«‚Æl‚¦‚éB

@D.@“K«‚ÌŒŸ“¢

@AVT‚̉‰ñ•]‰¿‹y‚ÑŽ¡—Ó™‚ðs‚Á‚½ê‡CˆÈ‰º‚Ì ‡@`‡A ‚ªl‚¦‚ç‚ê‚éB

@‡@@‚·‚ׂẴŠƒGƒ“ƒgƒŠ[‰ñ˜H‚ªEPS‚É‚æ‚Á‚Ä–³‹@”\‚Æ„’肳‚êCŒo‰ßŠÏŽ@’†‚ÉÄ”­‚ð”F‚ß‚È‚¢ê‡B

@‡A@‡@‚ð–ž‚½‚³‚È‚¢ê‡B

@1.@HDP‚ÌŠù‰‚ª‚ ‚éAVT

@Ä”­‚ª—\‘z‚³‚ê‚é‚Ì‚Å ‡@ ‚ð–ž‚½‚µ‚½ê‡‚ÍC–³§ŒÀ‚Ì“K«‚ð—L‚·‚éB‚½‚¾‚µCAf/AF/AT‚ÌŠù‰‚ª‚ ‚éê‡CÄ”­‚Ì‹°‚ê‚©‚çCŒ´‘¥‚Æ‚µ‚Ä•¡À‹@‚©‚Â’áG‹@ŽíŒÀ’è‚Æ‚·‚é‚ׂ«‚Å‚ ‚낤B

@2.@HDP‚ÌŠù‰‚ª‚È‚¢WPWÇŒóŒQ

@ƒJƒe[ƒeƒ‹ˆ’u‚ªŽ{s‚³‚ꂽꇂÍC‡@ ‚ð–ž‚½‚µ‚½ê‡‚Í–³§ŒÀ‚Ì“K«‚ð—L‚·‚éB‡A ‚Ìꇂɂ‚¢‚Ĉȉº‚ÅŒŸ“¢‚·‚éB

@‚±‚ê‚Ü‚Å‚Ì’mŒ©‚æ‚èCˆÈ‰º‚Ì’Ê‚è‚Æl‚¦‚ç‚ê‚éB

@1j@QRS≦120 msec‚ÌBŒ^‚ÍŠT‚ËFVP‚Å‚ ‚é27jB

@2j@ƒzƒ‹ƒ^[S“d}–”‚̓AƒfƒmƒVƒ“ƒeƒXƒg‚ÅQRS”g‚ÉŒ`‘ԕω»‚ª”F‚ß‚ç‚ꂽꇂ͕›“`“±˜H‚É‹@”\‚ª‚ ‚é‚Æl‚¦‚ç‚ê‚é27jB

@3j@¬l‚É‚¨‚¢‚ÄPSVT“™‚ÌŠù‰‚ª‚È‚¢WPWÇŒóŒQ‚ÌS“Ë‘RŽ€‚ÍC‚Ù‚Æ‚ñ‚Ç‹N‚±‚ç‚È‚¢3,5,17,25jB

@4j@Cohen‚ç‚Ìì‹Æ•”‰ï‚ÌŒ©‰ð‚ÍS“Ë‘RŽ€‚ÉŽåŠá‚ð’u‚¢‚Ä‚¨‚èC‰^“®•‰‰×ŒŸ¸‚ňÙ킪”F‚ß‚ç‚ê‚È‚©‚Á‚½‚Æ‚µ‚Ä‚àCHDP‚ð”Û’è‚·‚é‚É‚ÍŽŠ‚ç‚È‚¢B‚½‚¾‚µC‰^“®•‰‰×S“d}ŒŸ¸‚ðŽÀŽ{‚µ‚ÄCƒfƒ‹ƒ^”g‚ªÁŽ¸‚·‚é‚Ì‚Å‚ ‚ê‚ÎC•›“`“±˜H‚Ì‹@”\‚ª’á‚¢‚Æl‚¦‚ç‚ê‚éB‚©‚ÂC‰Á—î‚Æ‚Æ‚à‚É•›“`“±˜H‚Ì‹@”\‚ª’ቺ‚·‚é‚Æl‚¦‚ç‚ê‚é25jB

@5j@Goudevenos‚ç24j‹y‚ÑMunger‚ç‚Ì•ñ17j‚©‚çCusymptoms–”‚ÍSVTv‚ÌŠù‰‚ª‚È‚¢40ΈÈã‚Íusymptoms–”‚ÍSVTv‚ª‚Ù‚Ú‹N‚±‚ç‚È‚¢‚Æl‚¦‚ç‚ê‚邪C40Ζ¢–ž‚Å‚ ‚ê‚Έê’è‚ÌŠm—¦i”NŠÔ0.7`2%’ö“xj‚ÅdÇ“x‚ª•s–¾‚Ìusymptoms–”‚ÍSVTv‚Í‹N‚±‚肤‚é3,5,17jB‚½‚¾‚µCŒy”÷‚È—á‚âWPWÇŒóŒQ‚É”º‚í‚È‚¢‚à‚Ì‚àŠÜ‚Ü‚ê‚é‚Æl‚¦‚ç‚êC‰äX‚ª’è‹`‚µ‚½HDP‚ÍC‚»‚ê‚æ‚è‚à­‚È‚¢‚Æl‚¦‚ç‚ê‚éB‚È‚¨CÅ‚à‘€cŽm‚É‘¦‚µ‚½Fitzsimmons‚ç‚Ì•ñ3j‚̉äX‚É‚æ‚é‰ðÍ‚Å‚ÍC–³ÇŒó—á‚ÌHDP‚ÌV‹K”­Ç—¦‚Í”NŠÔ0.6%’ö“x‚Å‚ ‚Á‚½B–³ÇŒó—á‚ÌŠÔŒ‡«WPWÇŒóŒQ‚É‚¨‚¯‚é‰äX‚ª’è‹`‚µ‚½HDP‚ÌV‹K”­Ç—¦‚Í”NŠÔ0.2%’ö“x‚Å‚ ‚Á‚½B

@ã‹L‚ÌŒ©‰ð‚©‚çCˆê”ÊZ–¯‚Ì40ΈÈã‚Í‚Ù‚ÚHDP‚ð”­Ç‚µ‚È‚¢‚±‚Æ‚©‚çC“K«‚ð—L‚·‚邪CƒGƒrƒfƒ“ƒX‚Ì‚È‚¢‚G‹@Ží‚𜂭‚Æ‚µ‚½•û‚ª‚æ‚¢‚Å‚ ‚낤Bˆê•ûCV‹K”­Ç‚µ‚â‚·‚¢‚Ì‚Í40Ζ¢–ž‚ÌŽá”NŽÒ‘w‚Å‚ ‚èC‘€cŒoŒ±‚Ì󂢎Ⴂ‘€cŽÒ‚ÉHDP‚ª‹N‚±‚Á‚½ê‡‚É‚ÍCŽ–ŒÌ‚ɂ‚Ȃª‚è‚â‚·‚¢‚Æl‚¦‚ç‚ê‚éB‚½‚¾‚µCusymptoms–”‚ÍSVTv‚Ì”NŠÔ”­Ç—¦‚ª1%ˆÈã‚̉”\«‚à”Û’è‚Å‚«‚È‚¢‚ªCŽÀÛ‚ÌHDP‚ðŽ¦‚·‚à‚Ì‚Ì”­Ç—¦‚ÍCFitzsimmons‚ç‚Ì•ñ3j‚É‚æ‚ê‚Î1%–¢–ž‚Æl‚¦‚ç‚ê‚éBŠÔŒ‡«WPWÇŒóŒQ‚ÌꇂÍCHDP‚Ì•p“x‚Í‚³‚ç‚É’á‚¢‚Æl‚¦‚ç‚ê‚éB]‚Á‚ÄC40Ζ¢–ž‚ÌꇂÍCŒ´‘¥‚Æ‚µ‚Ä•¡À‹@‚©‚Â’áG‹@ŽíŒÀ’è‚Ì“K«‚ð—L‚·‚éB‚½‚¾‚µCˆÈ‰º‚Ìꇂɖ³§ŒÀ‚Ì“K«‚ð—L‚·‚é‚Æ‚µ‚Ä‚à‚æ‚¢‚Å‚ ‚낤B

@1j@QRS≦120 msec‚©‚ÂRosenbaum BŒ^B

@2j@ƒzƒ‹ƒ^[S“d}–”‚̓AƒfƒmƒVƒ“ƒeƒXƒg‚ðŽÀŽ{‚µCQRS”gŒ`‚ÌŒ`‘Ԃ̕ω»‚ð”F‚ß‚¸C‘©Ž}SŽº“`“±˜H‚ª„’肳‚ê‚éê‡B

@3j@ŠÔŒ‡«WPWÇŒóŒQ–”‚͉^“®•‰‰×ŒŸ¸‚É‚æ‚èƒfƒ‹ƒ^”g‚ÌÁŽ¸“™C•›“`“±˜H‚Ì’·‚¢‡s«—LŒø•s‰žŠú‚ª„’肳‚ê‚éê‡B

@3.@HDP‚ÌŠù‰‚ª‚È‚¢LGLÇŒóŒQ

@ƒJƒe[ƒeƒ‹ˆ’u‚ªŽ{s‚³‚ꂽꇂÍC‡@ ‚ð–ž‚½‚µ‚½ê‡‚Í–³§ŒÀ‚Ì“K«‚ð—L‚·‚éB‡A ‚Ìꇂɂ‚¢‚Ĉȉº‚ÅŒŸ“¢‚·‚éB

@Nielsen‚ç‚Ì•ñ19j‚ÍCƒfƒ‹ƒ^”g‚ðŽ¦‚µ‚½—á‚Í0.6%‚µ‚©‚È‚­CŽ–ŽÀãLGLÇŒóŒQ‚ÌŒŸ“¢‚Æ“¯“™‚Æl‚¦‚ç‚ê‚éB‚±‚±‚Å‚ÍCshort PRŽžŠÔ‚ª’Z‚­‚È‚ê‚΂Ȃé‚Ù‚ÇCŽá”NŽÒi’j—‚Æ‚à40‘ãj‚ÌAf‚Ì”­Ç—¦‚ª‚‚¢BNielsen‚ç‚Ì•ñ‚ð‰ðÍ‚·‚é‚ÆCAf‚Ì”NŠÔ”­Ç—¦‚ÍC1%–¢–ž‚Å‚ ‚èC—«‚Ìshort PRŽžŠÔŒQi≦121 msecj‚ƳíŒQi122-135 msecj‚ª‚Ù‚Ú“¯“™‚Å‚ ‚èC’j«‚Ìshort PRŽžŠÔŒQi≦129 msecj‚ͳíŒQi166-179 msecj‚Æ”ä‚ׂÄCŽá”N‚Å‚ ‚镪‚¾‚¯”NŠÔ”­Ç—¦‚ª’á‚¢BˆÈã‚Ì‚±‚Æ‚©‚ç‹É’[‚ÉPRŽžŠÔ‚ª’Z‚¢ŒQ‚𜂯‚ÎCŠT‚˳íŒQ‚Æ“¯“™‚ÌAf‚Ì”­Ç—¦‚Æl‚¦‚ç‚ê‚éB

@•ÄŠCŒRƒEƒF[ƒo[ƒKƒCƒh‚Å‚ÍCvery short PRŽžŠÔ iPRƒ100 msecj‚Ìꇂ͔ñNP“IS•]‰¿‚ª•K—v‚Å‚ ‚èCshort PRŽžŠÔ i≧100 msecj‚Ìꇂ͖³§ŒÀ‚Ì“K«‚ð—L‚·‚é‚Æ‚µ‚Ä‚¢‚éB‚±‚ê‚ÍNielsen‚ç‚Ì•ñ‚ðl—¶‚·‚é‚Æ‚±‚̂悤‚È“à—e‚Æ‚È‚èC‚킪‘‚Å‚à‚±‚ê‚É€‹’‚·‚ê‚΂悢‚Å‚ ‚낤B‚½‚¾CPRŽžŠÔ‚Ì‘ª’è‚͌뷂ª‚ ‚è9jCNielsen‚ç‚Ì•ñ19j‚ÌÅ­‚ÌPRŽžŠÔ‚Í104 msec‚Å‚ ‚Á‚½‚±‚Æ‚©‚çC110 msec’ö“x‚ð‹«ŠE‚Æ‚µC‚±‚ê–¢–ž‚ðq‹óˆãŠw“I‚ÈLGLÇŒóŒQ‚Æ‚·‚é‚ׂ«‚Å‚ ‚낤B‚½‚¾‚µCS“d}‚É‚Í20 msec’ö“x‚Ì‘ª’èŒë·‚ª¶‚¶“¾‚邱‚Æ‚©‚ç9jBŒJ‚è•Ô‚µŒŸ¸‚ðs‚Á‚Äf’f‚·‚é‚ׂ«‚Å‚ ‚éB

@LGLÇŒóŒQ‚Æf’f‚³‚ꂽꇂłàCNielsen‚ç‚Ì•ñ19j‚©‚çAf‚Ì”­Ç—¦‚ª‚킸‚©‚Éオ‚邾‚¯‚Å‚ ‚邱‚Æ‚©‚çC•¡À‹@‚©‚Â’áG‹@ŽíŒÀ’è‚Ì“K«‚ð—L‚·‚éBGrossman‚ç‚Ì•ñ6j‚©‚çCƒAƒfƒmƒVƒ“ƒeƒXƒg‚Í•›“`“±˜H‚Ì—L–³‚Ì„’è‚É—L—p‚Å‚ ‚é‚Æl‚¦‚ç‚ê‚邱‚Æ‚©‚çCƒzƒ‹ƒ^[S“d}–”‚̓AƒfƒmƒVƒ“ƒeƒXƒg‚ÌŒ‹‰Ê‚©‚çCQRS”gŒ`‚ÌŒ`‘Ԃ̕ω»‚ð”F‚ß‚¸C’˜–¾‚È•›“`“±˜H‚ª‚È‚¢‚Æ„’肳‚ê‚éꇂ͖³§ŒÀ‚Ì“K«‚ð—L‚·‚é‚Æ‚µ‚Ä‚æ‚¢‚Å‚ ‚낤B

@F.@AVT‚Ì“K«”»’èˆÄ

@ˆÈã‚ÌŒŸ“¢‚𓥂܂¦CAVT‚Ì“K«”»’èˆÄ‚ðTable 3‚ÉŽ¦‚µ‚½B‚È‚¨C’è‹`‚µ‚½HDP‚ð”F‚ß‚È‚©‚Á‚½ê‡‚Å‚àC—Õ°ˆãŠw“I‚ɃJƒe[ƒeƒ‹ˆ’u‚ª•K—v‚Æ‚³‚ꂽꇂ͎ÀŽ{‚·‚ׂ«‚Å‚ ‚éB

Table 3.@Proposed procedure of aeromedical fitness for the evaluation and assessment of atrioventricular tachyarrhythmias.
I.@–[Žº•p–¬«Ž¾Š³‚É‚¨‚¯‚錌—¬—ÍŠw“IŒ»ÛiHemodynamic Phenomena:HDPj‚ÌŠù‰‚Ì’è‹`
@ˆÈ‰º‚Ì‚¢‚¸‚ê‚©‚ð–ž‚½‚·‚à‚Ì‚ðŽw‚·B
A.@“®œ§C‚ß‚Ü‚¢CŽ¸_“™‚ÌzŠÂ“®‘Ԃ̈Ùí‚𔺂¤–[Žº•p–¬«Ž¾Š³‚ÌŠù‰‚ª‚ ‚éê‡
B.@WPW ÇŒóŒQ–”‚ÍLGL ÇŒóŒQ‚É‚¨‚¢‚ÄS–[ד®/S–[‘e“®/S–[•p”‚ÌŠù‰‚ª‚ ‚éê‡
C.@ã‹L‚ª•s–¾‚ÈꇂÍCŒo‰ßŠÏŽ@’†1j‚Ɉȉº‚Ì ‡@`‡B ‚¢‚¸‚ê‚©‚ð”F‚ß‚½ê‡
@@‡@@㎺«‚Ì•s®–¬‚ª10˜A”­ˆÈã‚©‚ÂS””170 bpmˆÈã‚ðŽ¦‚µ‚½‚à‚Ì
@@‡A@㎺«‚Ì•s®–¬‚ª30•bˆÈ㎑±‚µ‚½‚à‚ÌiS–[ד®/S–[‘e“®/S–[•p”2j‚𜂭j
@@‡B@WPW ÇŒóŒQ–”‚ÍLGL ÇŒóŒQ‚É‚¨‚¢‚ÄS–[ד®/S–[‘e“®/S–[•p”‚ð”F‚ß‚½ê‡
II.@q‹óˆãŠw‚É‚¨‚¯‚éf’fŠî€
@A.@WPWÇŒóŒQ
@@HDP‚ÌŠù‰‚Ì—L–³‚Í–â‚킸CˆÀÃŽžS“d}ãCshort PRŽžŠÔiPRƒ120 msecjCQRS„100 msec‹y‚уfƒ‹ƒ^”g‚ðŽ¦‚·ê‡B
@B.@LGLÇŒóŒQ
@@HDP‚ÌŠù‰‚Ì—L–³‚Í–â‚킸Cã‹L‚µ‚½WPWÇŒóŒQ‚̊𖞂½‚³‚¸CŒJ‚è•Ô‚µˆÀÃŽžS“d}‚𑪒肵‚½‚Ì‚É‚àŠÖ‚í‚炸very short PRŽžŠÔ iPRƒ110 msec’ö“xj‚ðPí“I‚É”F‚ß‚éê‡B
@C.@ã‹LˆÈŠO‚Ì–[Žº•p–¬«Ž¾Š³
@q‹óˆãŠw“K«‚ðŒ‡‚­‚Æ”»’f‚µCS‘Ÿ“d‹C¶—ŠwŒŸ¸‚É‚æ‚é•]‰¿‚ð—v‚·‚éB
III.@–[Žº•p–¬«Ž¾Š³‚Ìq‹óˆãŠw“K«”»’è—v—Ì
@A.@HDP‚ÌŠù‰‚ª‚ ‚éê‡
@@1.@S–[ד®/S–[‘e“®/S–[•p”‚ÌŠù‰2j
@@@@ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ÌŽÀŽ{‚Ì—L–³‚ð–â‚킸C‚·‚ׂẴŠƒGƒ“ƒgƒŠ[‰ñ˜H‚ªS‘Ÿ“d‹C¶—ŠwŒŸ¸‚É‚æ‚Á‚Ä–³‹@”\‚Æ„’肳‚êCŒo‰ßŠÏŽ@’†1j‚ÉHDP‚ð”F‚ß‚È‚¢ê‡C•¡À‹@‚©‚Â’áG‹@Ží3jŒÀ’è‚Ìq‹óˆãŠw“K«‚ð—L‚·‚éB
@@2.@ã‹LˆÈŠO
@@@@ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽÀŽ{‚µC‚·‚ׂẴŠƒGƒ“ƒgƒŠ[‰ñ˜H‚ªS‘Ÿ“d‹C¶—ŠwŒŸ¸‚É‚æ‚Á‚Ä–³‹@”\‚Æ„’肳‚êCŒo‰ßŠÏŽ@’†1j‚ÉHDP‚ð”F‚ß‚È‚¢ê‡‚ÍC–³§ŒÀ‚Ìq‹óˆãŠw“K«‚ð—L‚·‚éB
@B.@HDP‚ÌŠù‰‚ª‚È‚¢ê‡4j
@@1.@S‘Ÿ“d‹C¶—ŠwŒŸ¸‚ðŽÀŽ{‚µ‚Ä‚¢‚È‚¢WPWÇŒóŒQ
@@@@40ΈÈã:q‹óˆãŠw“K«‚ð—L‚·‚é5jB‚½‚¾‚µCˆÈ‰º‚Ì ‡@`‡B ‚ÌꇂÍC–³§ŒÀ‚Ìq‹óˆãŠw“K«‚ð—L‚·‚é‚Æ‚µ‚Ä‚à‚æ‚¢B
@@@@40Ζ¢–ž:•¡À‹@‚©‚Â’áG‹@Ží3jŒÀ’è‚Ìq‹óˆãŠw“K«‚ð—L‚·‚éB‚½‚¾‚µCˆÈ‰º‚Ì ‡@`‡B ‚ÌꇂÍC–³§ŒÀ‚Ìq‹óˆãŠw“K«‚ð—L‚·‚é‚Æ‚µ‚Ä‚à‚æ‚¢B
@@‡@@QRS≦120 msec‚©‚ÂRosenbaum BŒ^B
@@‡A@ƒzƒ‹ƒ^[S“d}–”‚̓AƒfƒmƒVƒ“ƒeƒXƒg‚ðŽÀŽ{‚µCQRS”gŒ`‚ÌŒ`‘Ԃ̕ω»‚ð”F‚ß‚¸C‘©Ž}SŽº“`“±˜H‚ª„’肳‚ê‚éê‡B
@@‡B@ŠÔŒ‡«WPWÇŒóŒQ–”‚͉^“®•‰‰×ŒŸ¸‚É‚æ‚èƒfƒ‹ƒ^”g‚ÌÁŽ¸“™C•›“`“±˜H‚Ì’·‚¢‡s«—LŒø•s‰žŠú‚ª„’肳‚ê‚éê‡B
@@2.@S‘Ÿ“d‹C¶—ŠwŒŸ¸‚ðŽÀŽ{‚µ‚Ä‚¢‚È‚¢LGLÇŒóŒQ
@@@@Œo‰ßŠÏŽ@1j‚ðŽÀŽ{‚µCHDP‚ð”F‚ß‚È‚¯‚ê‚Ε¡À‹@‚©‚Â’áG‹@Ží3jŒÀ’è‚Ìq‹óˆãŠw“K«‚ð—L‚·‚éB‚½‚¾‚µCƒzƒ‹ƒ^[S“d}–”‚̓AƒfƒmƒVƒ“ƒeƒXƒg‚ÌŒ‹‰Ê‚©‚çCQRS”gŒ`‚ÌŒ`‘Ԃ̕ω»‚ð”F‚ß‚¸C’˜–¾‚È•›“`“±˜H‚ª‚È‚¢‚Æ„’肳‚ê‚éꇂ͖³§ŒÀ‚Ìq‹óˆãŠw“K«‚ð—L‚·‚é‚Æ‚µ‚Ä‚æ‚¢B
@@3.@S‘Ÿ“d‹C¶—ŠwŒŸ¸‚ðŽÀŽ{‚µ‚½WPWÇŒóŒQ–”‚ÍLGLÇŒóŒQ
@@@@‚·‚ׂẴŠƒGƒ“ƒgƒŠ[‰ñ˜H‚ª–³‹@”\‚Å‚ ‚邱‚Æ‚ªS‘Ÿ“d‹C¶—ŠwŒŸ¸‚É‚æ‚Á‚Ä„’肳‚ꂽꇂ͖³§ŒÀ‚Ìq‹óˆãŠw“K«‚ð—L‚·‚éB
•t‹L
EŒo‰ßŠÏŽ@‚ð•K—v‚Æ‚µ‚È‚¢ê‡‚Å‚àC•K—v‚ɉž‚¶‚ÄŒo‰ßŠÏŽ@‚ðŽÀŽ{‚µ‚½•û‚ªˆÀ‘S‚Æl‚¦‚ç‚ê‚éB
EEbsteinŠïŒ`‚ÌꇂÍS‹@”\‚àŠÜ‚ß‚½¸¸‚ðs‚¤‚ׂ«‚Å‚ ‚éB
’‹L
@1j@Œo‰ßŠÏŽ@ŠúŠÔ‚Í6ƒ–ŒŽ‚ª“KØ‚Æl‚¦‚ç‚êC‚»‚ÌŠúŠÔ’†‚Í1ƒ–ŒŽ–ˆ‚̃zƒ‹ƒ^[S“d}‚ðŽÀŽ{‚·‚é‚ׂ«‚Å‚ ‚éB
@2j@S–[ד®/S–[‘e“®/S–[•p”‚ÌŠù‰‚Í•s“K‡‚Å‚ ‚éBWPW ÇŒóŒQ–”‚ÍLGL ÇŒóŒQˆÈŠO‚Ì–[Žº•p–¬«Ž¾Š³‚Å‚±‚ê‚ç‚ð”F‚ß‚½ê‡‚ÍC•Ê“r‚±‚ê‚ç‚ÌŒŸ“¢‚ª•K—v‚Å‚ ‚éB
@3j@’áG‹@Ží‚Æ‚ÍC2.5 GˆÈã‚Ì‚G‹@“®‚ðs‚í‚È‚¢‹@Ží‚ðŽw‚·B
@4j@’è‹`‚µ‚½HDP‚ð”F‚ß‚È‚©‚Á‚½ê‡‚Å‚àC—Õ°ˆãŠw“I‚ɃJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“–”‚ÍS‘Ÿ“d‹C¶—ŠwŒŸ¸‚ª•K—v‚Æ‚³‚ꂽꇂ͎ÀŽ{‚·‚ׂ«‚Å‚ ‚éB
@5j@‚G‹@Ží‚ð‘ÎÛ‚Æ‚µ‚½ƒGƒrƒfƒ“ƒX‚ª‚È‚¢‚½‚ßC’áG‹@Ží‚ÉŒÀ’è‚Æ‚µ‚½•û‚ª‚æ‚¢‚Æl‚¦‚ç‚ê‚éB

V.@I‚í‚è‚É

@¡‰ñCŽå‚Æ‚µ‚ÄWPWÇŒóŒQ‚ð‘ÎÛ‚Æ‚µ‚½AVT‚Ì“K«•]‰¿‹y‚Ñ”»’è–@‚ÌŒŸ“¢‚ðC‘“àŠO‚Ì—Õ°ˆãŠw“I’mŒ©‚¨‚æ‚Ñq‹óˆãŠw“I’mŒ©‚ÉŠî‚¢‚Äs‚Á‚½B“K«‚Ì”»’è‹@ŠÖ‚ÍC‰Â”\‚ÈŒÀ‚è‰ÈŠw“Iª‹’‚ÉŠî‚¢‚½“ˆêŒ©‰ð‚ð‚à‚Á‚ÄCR¸‚̉^—p‚ðs‚¤‚±‚Æ‚ªd—v‚Å‚ ‚èC‚»‚ÌŒö³‚ÈR¸E”»’è‚ÌŽ‘‚Æ‚È‚é‚悤‚È’ñˆÄ‚ðŽŽ‚Ý‚½B

@‚킪‘‚Å‚G‹@Žíi–¯ŠÔ‚Ì‹ÈŒ|”òs“™‚Íœ‚­j‚Ì‹Æ–±‚ðs‚¤‘€cŽm‚ÍCq‹óŽ©‰q‘à‚Ì‚Ý‚ÌŠ‘®‚ƂȂ邪Cq‹óŽ©‰q‘à‚Ì‹K‘¥12j‚Å‚ÍC‘€cŽmŒó•â¶‚ÌS“d}ãWPWÇŒóŒQ‚ð”F‚ß‚½ê‡‚Í“K«‚ðŒ‡‚­‚±‚Æ‚Æ‚È‚Á‚Ä‚¢‚éB]‚Á‚ÄCq‹óŽ©‰q‘à‚É‚¨‚¢‚Ä40ΈÈã‚ʼn‚ß‚ÄS“d}ãWPWÇŒóŒQ‚ð”­Œ©‚³‚ê‚é—á‚Í’Êí‚ ‚肦‚È‚¢‚±‚Æ‚©‚çCEPS‚ðŽÀŽ{‚µ‚Ä‚¢‚È‚¢WPWÇŒóŒQ‚Ì40ΈÈã‚ð’áG‹@ŽíŒÀ’è‚É‚µ‚Ä‚à‰^—pã“Á‚É–â‘肪‚È‚¢‚Å‚ ‚낤B

@‚킪‘‚̃EƒF[ƒo[R¸‚ÍC‘“yŒð’ÊÈiq‹ó‹Çj‚Æ–h‰qÈiŽ©‰q‘àj‚É‚¨‚¢‚Ä‚»‚ꂼ‚ê‚ÌR¸‹@ŠÖ‚Ås‚í‚ê‚Ä‚¢‚邪C‚»‚ÌR¸‚̓P[ƒXƒoƒCƒP[ƒX‚Ås‚í‚ê‚邱‚Æ‚ª‘½‚­C‰ÈŠw“Iª‹’‚ÉŠî‚¢‚½“ˆê“I‚ȃKƒCƒhƒ‰ƒCƒ“‚Í‚È‚¢B‰äX‚Ì’ñˆÄ‚ªC‚±‚̃KƒCƒhƒ‰ƒCƒ“‚Ì쬂ɂ‚Ȃª‚èC“K«•]‰¿E”»’è‚Ɉȉº‚ÌŒø‰Ê‚ð—^‚¦‚邱‚Æ‚ðŠú‘Ò‚µ‚Ä‚¢‚éB

@‡@@“K«•]‰¿‹y‚Ñ”»’è–@‚Ì–¾Šm‰»B

@‡A@”»’è‚ÌŒö•½«‚̈ێB

@‡B@”»’è‚ðs‚¤‘O‚ɃXƒNƒŠ[ƒjƒ“ƒO‚ðs‚¤‚±‚Æ‚É‚æ‚èCŒŸ¸”ï—pC\¿ŽÒ‚ÌSg“I‚È•‰’SC”»’èŽÒ‚Ì•‰’S“™‚Ì‘¹Ž¸‚ð–h‚®‚±‚Æ‚ª‚Å‚«‚éB

@–{“à—e‚Í2015”N6ŒŽŽž“_‚Å‚ÌŒ©‰ð‚ɂ‚¢‚Ä‹LÚ‚µ‚½B¡Œã‚Ì’mŒ©‹y‚шãŠw‚Ìi•à‚É‚Ä“à—e‚ÌÄŒŸ“¢‚ði‚ß‚é‚ׂ«‚Æl‚¦‚ç‚ê‚éB

VI.@ŽÓŽ«

@–{ŒŸ“¢‚É‚ ‚½‚èCzŠÂŠíŠw‚ÉŠÖ‚·‚é‹Md‚Ȍ䕌¾‚ðŽ’‚è‚Ü‚µ‚½•ô­‹MˆãŠ¯‚É‹Þ‚ñ‚ÅŒä—ç\‚µã‚°‚Ü‚·B

•¶@@@Œ£

1j Air Force Waiver Guide, Last Update:28 May 2013.
http://www.wpafb.af.mil/shared/media/document/AFD-130118-045.pdf#search=fAir+Force+Waiver+Guidef, iaccessed 2015-05-28j.

2j ’²—¥ˆÙí‚̎戵‚¢‚ɂ‚¢‚ÄC‘‹óq‘æ687†C•½¬25”N11ŒŽ27“úD

3j Fitzsimmons, P.J., McWhirter, P.D., Peterson, D.W. and Kruyer, W.B.:The natural history of Wolff-Parkinson-White syndrome in 228 military aviators:a long-term follow-up of 22 years.@Am. Heart J., 142, 530-536, 2001.

4j “¡–Ø@–¾:–[ŽºƒŠƒGƒ“ƒgƒŠ[«•p”C•ÊûzŠÂŠíÇŒóŒQIC“ú–{—Õ°Cpp. 578-582, 2007.

5j Goudevenos, J.A., Katsouras, C.S., Graekas, G., Argiri, O., Giogiakas, V. and Sideris, D.A.:Ventricular pre-excitation in the general population:a study on the mode of presentation and clinical course.@Heart, 83, 29-34, 2000.

6j Grossman, A., Wand, O., Matezki, S., Kerner, A., Assa, A. and Glikson, M.:Use of adenosine test for the exclusion of preexcitation syndrome in asymptomatic individuals.@Ann. Noninvasive Electrocardiol., 16, 180-183, 2011.

7j –I’J@mC•½”öŒ©ŽO:Lown-Ganong-LevineÇŒóŒQC•ÊûzŠÂŠíÇŒóŒQIC“ú–{—Õ°Cpp. 212-215, 2007.

8j –I’J@mC•½”öŒ©ŽO:‘Šú‹»•±ÇŒóŒQC•ÊûzŠÂŠíÇŒóŒQIC“ú–{—Õ°Cpp. 413-418, 2007.

9j Josephson, M.E. and Kastor, J.A.:Supraventricular tachycardia in Lown-Ganong-Levine syndrome:atrionodal versus intranodal reentry.@Am. J. Cardiol., 40, 521-527, 1977.

10j –Ø‘º—²‰îCŠ}ŠÑ@G:”­ì«ãŽº«•p”C•ÊûzŠÂŠíÇŒóŒQIC“ú–{—Õ°Cpp. 586-589, 2007.

11j ‹M“c‰ª¬Œ›Cˆä㊰ˆê:Wolff-Parkinson-WhiteÇŒóŒQC•ÊûzŠÂŠíÇŒóŒQIC“ú–{—Õ°Cpp. 239-243, 2007.

12j q‹óŽ©‰q‘àq‹óg‘ÌŒŸ¸‹K‘¥Cq‹óŽ©‰q‘à’B‘æ19†Cº˜a54”N8ŒŽ3“ú iÅI‰ü³:•½¬24”N3ŒŽ29“úCq‹óŽ©‰q‘à’B‘æ25†jD

13j q‹óg‘ÌŒŸ¸ƒ}ƒjƒ…ƒAƒ‹C‘‹óæ‘æ531†C•½¬19”N3ŒŽ2“úiÅI‰ü³:•½¬25”N11ŒŽ27“úC‘‹óq‘æ684†jD

14j q‹óg‘ÌŒŸ¸‚ÉŠÖ‚·‚éŒP—ßC–h‰q’¡ŒP—ß‘æ1†Cº˜a33”N1ŒŽ6“úiÅI‰ü³:•½¬26”N1ŒŽ24“úCÈŒP‘æ1†jD

15j Manual of Civil Aviation Medicine, Third Edition 2012.
http://www.icao.int/safety/aviation-medicine/Documents/8984_cons_en.pdf#search=fManual+of+Civil+Aviation+Medicinef, iaccessed 2015-05-28j.

16j …–qŒ÷ˆê:–[ŽºŒ‹ßƒŠƒGƒ“ƒgƒŠ[•p”C–[ŽºŒ‹ß•”ƒŠƒGƒ“ƒgƒŠ[•p”C•ÊûzŠÂŠíÇŒóŒQIC“ú–{—Õ°Cpp. 564-569, 2007.

17j Munger, T.M., Packer, D.L., Hammill, S.C., Feldman, B.J., Bailey, K.R., Ballard, D.J., Holmes, D.R. Jr. and Gersh, B.J.:A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989.@Circulation, 87, 866-873, 1993.

18j ’†“‡‰pŽqCŒF’J_ˆê˜Y:Regular narrow QRS tachycardia‚ÌŠÓ•Êf’f‚ÆŽ¡—ÃC“ú–{“à‰ÈŠw‰ïŽGŽC95, 299-304, 2006.

19j Nielsen, J.B., Pietersen, A., Graff, C., Lind, B., Struijk, J.J., Olesen, M.S., Haunsø, S., Gerds, T.A., Ellinor, P.T., Kober, L., Svendsen, J.H. and Holst, A.G.:Risk of atrial fibrillation as a function of the electrocardiographic PR interval:results from the Copenhagen ECG Study.@Heart Rhythm, 10, 1249-1256, 2013.

20j ¼èŒõO:Wide QRS •p”‚ÌŠÓ•Êf’f‚ÆŽ¡—ÃC“ú–{“à‰ÈŠw‰ïŽGŽC95, 305-313, 2006.

21j ¬ì@‘C‘ŠàV‹`–[CÂÀ˜a—²C‰Æâ‹`lCÎì—˜”VCˆäã@”ŽC‰œ‘º@ŒªC‰Á“¡‹M—YCŠ™‘qŽj˜YCŒF’J_ˆê˜YCŒI“c—²ŽuC¬âˆä‰Ã•vC¬—Ñ—mˆêC¯“cŽç’jC™@@ŒOCZ—F’¼•ûC‚ŒŽ½ŽiC‚–ö@Š°C’†—¢—S“ñC•½ˆä^—C“n•Óˆê˜YCŠâ²@“ÄC‘å¼@“NC‹v‰êŒ\—SC¬—Ñ‹`“TC—¢Œ©˜a_C’O–ì@ˆèC’rŽå‰ëbC‰i£@‘C“¡–Ø@–¾CˆÀ“c³”V:—Õ°S‘Ÿ“d‹C¶—ŒŸ¸‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“i2011”N‰ü’ù”ÅjD
http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawas_h.pdf
iŽQÆ2015-05-28j.

22j ‰œ‘º@ŒªC‘ŠàV‹`–[C‘ŠŒ´’¼•FCÂÀ˜a—²C‰«d@ŒOCŒF’J_ˆê˜YC¯“cŽç’jCZ—F’¼•ûC‚‹´@~C“à“¡Ž lC’†‘ºDGC–ì㺕FC•½”öŒ©ŽOC¼–{–œ•vC‘ºì—T“ñCŽRª’õˆêC‘å˜a“c^ŒºC²X–Ø^ŒáC—¢Œ©˜a_Cšê“c@_C’rŽå‰ëbC–I’J@mCV@”ŽŽŸC‰Æâ‹`lCŸN“ct…C“›ˆä—T”VCŽO“c‘ºG—Y:ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì“K‰ž‚ÆŽè‹Z‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“D
http://www.j-circ.or.jp/guideline/pdf/JCS2012_okumura_h.pdfiŽQÆ2015-05-28j.

23j ‰œ‘º@ŒªC‘ŠàV‹`–[CÂÀ˜a—²Cˆé•”•¶—²C‘å¼@“NC‰Á“¡‹M—YC´…º•FCV“c@—²C”‹Œ´½‹vC¼–{–œ•vC‘ºì—T“ñCÎì—˜”VCŠâ@@‹œC”~‘º@ƒC‘–쌤ŒáCŒI“c—²ŽuC²X–Ø^ŒáCŽu‰ê@„C¯“cŽç’jCZ—F’¼•ûC’†—¢—S“ñC’†‘ºDGC’ë–ìTˆêC•½”öŒ©ŽOC‘å]@“§CŠ}ŠÑ@GC–Ø‘º@„CŽ™‹Êˆí—YC“c’†–Εv:•s®–¬‚Ì”ñ–ò•¨Ž¡—ÃKƒCƒhƒ‰ƒCƒ“i2011”N‰ü’ù”Åj.
http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_d.pdfiŽQÆ2015-05-28j.

24j Pappone, C., Santinelli, V., Manguso, F., Augello, G., Santinelli, O., Vicedomini, G., Gulletta, S., Mazzone, P., Tortoriello, V., Pappone, A., Dicandia, C. and Rosanio, S.:A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome.@N. Engl. J. Med., 349, 1803-1811, 2003.

25j Pediatric and Congenital Electrophysiology Society iPACESj;Heart Rhythm Society iHRSj;American College of Cardiology Foundation iACCFj;American Heart Association iAHAj;American Academy of Pediatrics iAAPj;Canadian Heart Rhythm Society iCHRSj, Cohen, M.I., Triedman, J.K., Cannon, B.C., Davis, A.M., Drago, F., Janousek, J., Klein, G.J., Law, I.H., Morady, F.J., Paul, T., Perry, J.C., Sanatani, S. and Tanel, R.E.:PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White iWPW, ventricular preexcitationj electrocardiographic pattern:developed in partnership between the Pediatric and Congenital Electrophysiology Society iPACESj and the Heart Rhythm Society iHRSj. Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation iACCFj, the American Heart Association iAHAj, the American Academy of Pediatrics iAAPj, and the Canadian Heart Rhythm Society iCHRSj.@Heart Rhythm, 9, 1006-1024, 2012.

26j Rosenbaum, F.F., Hecht, H.H. and Wilson, F.N.:The potential variations of the thorax and the esophagus in anomalous atrioventricular excitation iWolff-Parkinson-White syndromej.@Am. Heart J., 29, 281-326, 1945.

27j Suzuki, T., Nakamura, Y., Yoshida, S., Yoshida, Y. and Shintaku, H.:Differentiating fasciculoventricular pathway from Wolff-Parkinson-White syndrome by electrocardiography.@Heart Rhythm, 11, 686-690, 2014.

28j “cç³W‹vC‰¡“c‘Žj:ŠúŠOŽûkmS–[«C–[ŽºÚ‡•”«CSŽº«nC•ÊûzŠÂŠíÇŒóŒQIC“ú–{—Õ°Cpp. 299-296.

29j U. S. Navy Aeromedical Reference and Waiver Guide, April 30, 2015.
http://www.med.navy.mil/sites/nmotc/nami/arwg/Documents/Complete_Waiver_Guide_150430.pdf, iaccessed 2015-05-28j.

30j Wiener, I.:Syndromes of Lown-Ganong-Levine and enhanced atrioventricular nodal conduction.@Am. J. Cardiol., 52, 637-639, 1983.

31j ŽR“àNÆ:ŽÀ’nˆã‰Æ‚É‹‚ß‚ç‚ê‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Â̒mŽ¯‚Æ“úíf—Âւ̉ž—pCƒAƒuƒŒ[ƒVƒ‡ƒ“‚ŪŽ¡‚ª“¾‚ç‚ê‚â‚·‚¢•p”‚Æ“¾‚ç‚ê‚É‚­‚¢•p”CMedical Practice, 27, 1835-1840, 2010.

32j ‹g‰êN—TC´…º•FC¼è‰v“¿:¶–[‹NŒ¹S–[•p”B•ÊûzŠÂŠíÇŒóŒQIC“ú–{—Õ°Cpp. 338-341, 2007.

˜A—æ:§359-8513@é‹ÊŒ§Š‘òŽs•À–Ø3-2
@@@–h‰qˆã‰È‘åŠwZ–h‰qˆãŠwŒ¤‹†ƒZƒ“ƒ^[ˆÙíŠÂ‹«‰q¶Œ¤‹†•”–å
@@@îà“c@–M•v
@@@E-mail:takada@ndmc.ac.jp